



10/10/00

3078 U.S. PO

Type a plus (+) inside this box - ☒

10-11-00

A

Box SEQ

PTOSB28 (12/97)

Approved for use through 09/30/00. OMB 0651-0032
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

**UTILITY
PATENT APPLICATION
TRANSMITTAL**

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Attorney Docket No. 7991-086 Total Pages 63

First Named Inventor or Application Identifier

Beetham et al.

Express Mail Label No. EL 501 634 414 US

APPLICATION ELEMENTS

See MPEP chapter 600 concerning utility patent application contents.

ADDRESS TO: Assistant Commissioner for Patents
Box Patent Application
Washington, DC 20231

1. ☒ Fee Transmittal Form
Submit an original, and a duplicate for fee processing)
2. ☒ Specification including Table of Contents [Total Pages 31]
(preferred arrangement set forth below)

-Descriptive title of the invention
-Cross Reference to Related Applications
-Statement Regarding Fed sponsored R&D
-Reference to Microfiche Appendix
-Background of the Invention
-Brief Summary of the Invention
-Brief Description of the Drawings (if filed)
-Detailed Description of the Invention (including drawings, if filed)
-Claim(s)
-Abstract of the Disclosure

3. ☒ Drawing(s) (35 USC 113) [Total Sheets 10]

4. ☒ Oath or Declaration [Total Sheets 2]

- a. ☐ Newly executed (original or copy)
b. ☐ Copy from a prior application (37 CFR 1.63(d))
(for continuation/divisional with Box 17 completed)

[Note Box 5 below]

- i. ☐ **DELETION OF INVENTOR(S)**

Signed statement attached deleting inventor(s) named in the prior application, see 37 CFR 1.63(d)(2) and 1.33 (b).

5. ☐ Incorporation By Reference (useable if Box 4b is checked)
The entire disclosure of the prior application, from which a copy of the oath or declaration is supplied under Box 4b, is considered as being part of the disclosure of the accompanying application and is hereby incorporated by reference therein.

6. ☐ Microfiche Computer Program (Appendix)
7. ☒ Nucleotide and/or Amino Acid Sequence Submission
(if applicable, all necessary)
- a. ☒ Computer Readable Copy
- b. ☐ Paper Copy (identical to computer copy)
- c. ☒ Statement verifying identity of above copies

ACCOMPANYING APPLICATION PARTS

8. ☐ Assignment Papers (cover sheet & document(s))
9. ☐ 37 CFR 3.73(b) Statement ☐ Power of Attorney
(when there is an assignee)
10. ☐ English Translation Document *(if applicable)*
11. ☐ Information Disclosure ☐ Copies of IDS
Statement (IDS)/PTO-1449 Citations
12. ☐ Preliminary Amendment
13. ☒ Return Receipt Postcard (MPEP 503)
(Should be specifically itemized)
14. ☐ Small Entity ☐ Statement filed in prior application,
Statement(s) Status still proper and desired
15. ☐ Certified Copy of Priority Document(s)
(if foreign priority is claimed)
16. ☐ Other:

17. If a **CONTINUING APPLICATION**, check appropriate box and supply the requisite information:

☐ Continuation ☐ Divisional ☐ Continuation-in-part (CiP) of prior application No: filed.

18. CORRESPONDENCE ADDRESS

☒ Customer Number or Bar Code Label 20583
(Insert Customer No. or Attach bar code label here) ☐ Correspondence address below

NAME			
ADDRESS			
CITY	STATE	ZIP CODE	
COUNTRY	TELEPHONE	FAX	

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Box Patent Application, Washington, DC 20231.

PENNIE & EDMONDS LLP
 COUNSELLORS AT LAW
 1155 Avenue of the Americas
 New York, N.Y. 10036-2711
 (212) 790-9090

ATTORNEY DOCKET NO. 7991-086Date: October 10, 2000

Assistant Commissioner for Patents
 Box PATENT APPLICATION
 Washington, D.C. 20231

Sir:

The following utility patent application is enclosed for filing:

Applicant(s): Beetham et al.Executed on: unexecutedTitle of Invention: NON-TRANSGENIC HERBICIDE RESISTANT PLANTS**PATENT APPLICATION FEE VALUE**

TYPE	NO. FILED	LESS	EXTRA	EXTRA RATE	FEE
Total Claims	38	-20	18	\$18.00 each	\$ 324.00
Independent	5	-3	2	\$80.00 each	\$ 160.00
Minimum Fee					\$ 710.00
Multiple Dependency Fee If Applicable (\$270.00)					\$ 270.00
Total					\$ 1,464.00
50% Reduction for Independent Inventor, Nonprofit Organization or Small Business Concern (a verified statement as to the applicant's status is attached)					- \$ 0.00
Total Filing Fee					\$ 1,464.00

⊗ This application claims priority to U.S. Provisional Application No. 60/158,027, filed on October 7, 1999 and
 U.S. Provisional Application No. 60/173,564, filed December 30, 1999.

Please charge the required fee to Pennie & Edmonds LLP Deposit Account No. 16-1150. A copy of this sheet is
 enclosed.

Respectfully submitted,

Thomas E. Friebe
Thomas E. Friebe ^{REC'D} 40,203 29,258
 Thomas E. Friebe
 PENNIE & EDMONDS LLP (Reg. No.)

Enclosure

This form is not for use with continuation, divisional, re-issue, design or plant patent applications.

NON-TRANSGENIC HERBICIDE RESISTANT PLANTS

TABLE OF CONTENTS

5	1.	FIELD OF THE INVENTION	1
	2.	BACKGROUND TO THE INVENTION	1
	2.1	PHOSPHONOMETHYLGLYCINE HERBICIDES	1
10	2.2	RECOMBINAGENIC OLIGONUCLEOBASES	3
	3.	SUMMARY OF THE INVENTION	4
	3.1	DEFINITIONS	5
15	4.	BRIEF DESCRIPTION OF THE FIGURES	7
	5.	DETAILED DESCRIPTION OF THE INVENTION	8
	5.1	RECOMBINAGENIC OLIGONUCLEOBASES	9
	5.2	THE LOCATION AND TYPE OF MUTATION INTRODUCED INTO THE EPSPS GENE	14
20	5.3	THE DELIVERY OF RECOMBINAGENIC OLIGONUCLEOBASES INTO PLANT CELLS	18
	5.3.1	MICROCARRIERS AND MICROFIBERS	18
	5.3.2	PROTOPLAST ELECTROPORATION	19
	5.3.3	WHISKERS AND MICROINJECTION	20
25	5.4	SELECTION OF GLYPHOSATE RESISTANT PLANTS	20
	6.	EXAMPLE	20
	6.1	MATERIAL AND METHODS	20
30	6.1.1	ISOLATION OF <i>ARABIDOPSIS THALIANA</i> EPSPS cDNA	20
	6.1.2	PREPARATION OF THE EXPRESSION VECTOR	21
	6.1.3	CLONING OF THE ARABIDOPSIS EPSPS GENE INTO BACTERIAL EXPRESSION VECTOR	21
35	6.1.4	NOVEL POINT MUTATIONS IN THE EPSPS GENE	21
	6.1.5	GLYPHOSATE RESISTANCE ASSAYS	22

	<u>Page</u>
6.1.7 ISOLATION AND PURIFICATION OF THE EXPRESSED PROTEIN FROM BACTERIAL CLONES	22
5	
6.2 RESULTS	23
WE CLAIM:	24
10 ABSTRACT	29
15	
20	
25	
30	
35	

NON-TRANSGENIC HERBICIDE RESISTANT PLANTS

The present application claims priority to U.S. Provisional Application No. 60/158,027, filed on October 7, 1999 and to U.S. Provisional Application No. 60/173,564, filed December 30, 1999, the disclosures of each of which are incorporated by reference herein in their entirety.

1. FIELD OF THE INVENTION

The present invention relates to the production of a non-transgenic plant resistant or tolerant to a herbicide of the phosphonomethylglycine family, *e.g.*, glyphosate. The present invention also relates to the use of a recombinagenic oligonucleobase to make a desired mutation in the chromosomal or episomal sequences of a plant in the gene encoding for 5-enol pyruvylshikimate-3-phosphate synthase (EPSPS). The mutated protein, which substantially maintains the catalytic activity of the wild-type protein, allows for increased resistance or tolerance of the plant to a herbicide of the phosphonomethylglycine family, and allows for the substantially normal growth or development of the plant, its organs, tissues or cells as compared to the wild-type plant irrespective of the presence or absence of the herbicide. The present invention also relates to a non-transgenic plant cell in which the EPSPS gene has been mutated, a non-transgenic plant regenerated therefrom, as well as a plant resulting from a cross using a regenerated non-transgenic plant having a mutated EPSPS gene.

2. BACKGROUND TO THE INVENTION

2.1 PHOSPHONOMETHYLGLYCINE HERBICIDES

Herbicide-tolerant plants may reduce the need for tillage to control weeds thereby effectively reducing soil erosion. One herbicide which is the subject of much investigation in this regard is N-phosphonomethylglycine, commonly referred to as glyphosate. Glyphosate inhibits the shikimic acid pathway which leads to the biosynthesis of aromatic compounds including amino acids, hormones and vitamins. Specifically, glyphosate curbs the conversion of phosphoenolpyruvic acid (PEP) and 3-phosphoshikimic acid to 5-enolpyruvyl-3-phosphoshikimic acid by inhibiting the enzyme 5-enolpyruvylshikimate-3-phosphate synthase (hereinafter referred to as EPSP synthase or EPSPS). For purposes of the present invention, the term "glyphosate" includes any herbicidally effective form of N-phosphonomethylglycine (including any salt thereof), other forms which result in the production of the glyphosate anion in plants and any other herbicides of the phosphonomethylglycine family.

Tolerance of plants to glyphosate can be increased by introducing a mutant EPSPS gene having an alteration in the EPSPS amino acid coding sequence into the genome of the plant. Examples of some of the mutations in the EPSPS gene for inducing glyphosate tolerance are described in the following patents: U.S. Patent No. 5,310,667; U.S. Patent No. 5,866,775; U.S. Patent No. 5,312,910; U.S. Patent No. 5,145,783. These proposed mutations typically have a higher K_i for glyphosate than the wild-type EPSPS enzyme which confers the glyphosate-tolerant phenotype, but these variants are also characterized by a high K_m for PEP which makes the enzyme kinetically less efficient (Kishore et al., 1988, Ann. Rev. Biochem. 57:627-663; Schulz et al., 1984, Arch. Microbiol. 137: 121-123; Sost et al., 1984, FEBS Lett. 173: 238-241; Kishore et al., 1986, Fed. Proc. 45: 1506; Sost and Amrhein, 1990, Arch. Biochem. Biophys. 282: 433-436). Many mutations of the EPSPS gene are chosen so as to produce an EPSPS enzyme that is resistant to herbicides, but unfortunately, the EPSPS enzyme produced by the mutated EPSPS gene has a significantly lower enzymatic activity than the wild-type EPSPS. For example, the apparent K_m for PEP and the apparent K_i for glyphosate for the wild-type EPSPS from *E. coli* are 10 μ M and 0.5 μ M, while for a glyphosate-tolerant isolate having a single amino acid substitution of alanine for glycine at position 96, these values are 220 μ M and 4.0 mM, respectively. A number of glyphosate-tolerant EPSPS genes have been constructed by mutagenesis. Again, the glyphosate-tolerant EPSPS had lower catalytic efficiency (V_{max}/K_m), as shown by an increase in the K_m for PEP, and a slight reduction of the V_{max} of the wild-type plant enzyme (Kishore et al., 1988, Ann. Rev. Biochem. 57:627-663).

Since the kinetic constants of the variant enzymes are impaired with respect to PEP, it has been proposed that high levels of overproduction of the variant enzyme, 40-80 fold, would be required to maintain normal catalytic activity in plants in the presence of glyphosate (Kishore et al., 1988, Ann. Rev. Biochem. 57:627-663). It has been shown that glyphosate-tolerant plants can be produced by inserting into the genome of the plant the capacity to produce a higher level of EPSP synthase in the chloroplast of the cell (Shah et al., 1986, Science 233, 478-481), which enzyme is preferably glyphosate-tolerant (Kishore et al., 1988, Ann. Rev. Biochem. 57:627-663).

The introduction of the exogenous mutant EPSPS genes into plant is well documented. For example, according to U.S. Patent No. 4,545,060, to increase a plant's resistance to glyphosate, a gene coding for an EPSPS variant having at least one mutation that renders the enzyme more resistant to its competitive inhibitor, *i.e.*, glyphosate, is introduced into the plant genome. However, many complications and problems are associated with these examples. Many such mutations result in low expression of the mutated EPSPS gene product or result in an EPSPS gene product with significantly lower

enzymatic activity as compared to wild type. The low expression or low enzymatic activity of the mutated enzyme results in abnormally low levels of growth and development of the plant.

While such variants in the EPSP synthases have proved useful in obtaining
5 transgenic plants tolerant to glyphosate, it would be increasingly beneficial to obtain a variant EPSPS gene product that is highly glyphosate-tolerant but still kinetically efficient, such that improved tolerance can be obtained with a wild-type expression level.

2.2 RECOMBINAGENIC OLIGONUCLEOBASES

10 Recombinagenic oligonucleobases and their use to effect genetic changes in eukaryotic cells are described in United States patent No. 5,565,350 to Kmiec (Kmiec I). Kmiec I teaches a method for introducing specific genetic alterations into a target gene. Kmiec I discloses, *inter alia*, recombinagenic oligonucleobases having two strands, in which a first strand contains two segments of at least 8 RNA-like nucleotides that are
15 separated by a third segment of from 4 to about 50 DNA-like nucleotides, termed an "interposed DNA segment." The nucleotides of the first strand are base paired to DNA-like nucleotides of a second strand. The first and second strands are additionally linked by a segment of single stranded nucleotides so that the first and second strands are parts of a single oligonucleotide chain. Kmiec I further teaches a method for introducing specific
20 genetic alterations into a target gene. According to Kmiec I, the sequences of the RNA segments are selected to be homologous, *i.e.*, identical, to the sequence of a first and a second fragment of the target gene. The sequence of the interposed DNA segment is homologous with the sequence of the target gene between the first and second fragment except for a region of difference, termed the "heterologous region." The heterologous
25 region can effect an insertion or deletion, or can contain one or more bases that are mismatched with the sequence of target gene so as to effect a substitution. According to Kmiec I, the sequence of the target gene is altered as directed by the heterologous region, such that the target gene becomes homologous with the sequence of the recombinagenic oligonucleobase. Kmiec I specifically teaches that ribose and 2'-O-methylribose, *i.e.*, 2'-methoxyribose, containing nucleotides can be used in recombinagenic oligonucleobases and that naturally-occurring deoxyribose-containing nucleotides can be used as DNA-like
30 nucleotides.

U.S. Patent No. 5,731,181 to Kmiec (Kmiec II) specifically disclose the use of recombinagenic oligonucleobases to effect genetic changes in plant cells and discloses
35 further examples of analogs and derivatives of RNA-like and DNA-like nucleotides that can be used to effect genetic changes in specific target genes. Other patents discussing the use

of recombinagenic oligonucleobases include: U.S. Patent Nos. 5,756,325; 5,871,984; 5,760,012; 5,888,983; 5,795,972; 5, 780,296; 5,945,339; 6,004,804; and 6,010,907 and in International Patent No. PCT/US00/23457; and in International Patent Publication Nos. WO 98/49350; WO 99/07865; WO 99/58723; WO 99/58702; and WO 99/40789.

- 5 Recombinagenic oligonucleobases include mixed duplex oligonucleotides, non-nucleotide containing molecules taught in Kmiec II and other molecules taught in the above-noted patents and patent publications.

Citation or identification of any reference in Section 2, or any section of this application shall not be construed as an admission that such reference is available as prior art to the present invention.

3. SUMMARY OF THE INVENTION

The present invention is directed to a non-transgenic plant or plant cell having one or more mutations in the EPSPS gene, which plant has increased resistance or tolerance to a member of the phosphonomethylglycine family and which plant exhibits substantially normal growth or development of the plant, its organs, tissues or cells, as compared to the corresponding wild-type plant or cell. The present invention is also directed to a non-transgenic plant having a mutation in the EPSPS gene, which plant is resistant to or has an increased tolerance to a member of the phosphonomethylglycine family, *e.g.*, glyphosate, wherein the mutated EPSPS protein has substantially the same catalytic activity as compared to the wild-type EPSPS protein.

The present invention is also directed to a method for producing a non-transgenic plant having a mutated EPSPS gene that substantially maintains the catalytic activity of the wild-type protein irrespective of the presence or absence of a herbicide of the phosphonomethylglycine family. The method comprises introducing into a plant cell a recombinagenic oligonucleobase with a targeted mutation in the EPSPS gene and identifying a cell, seed, or plant having a mutated EPSPS gene.

Illustrative examples of a recombinagenic oligonucleobase is found in following patent publications, which are incorporated in their entirety by reference herein:

30 U.S. Patent Nos. 5,565,350; 5,756,325; 5,871,984; 5,760,012; 5,731,181; 5,888,983; 5,795,972; 5, 780,296; 5,945,339; 6,004,804; and 6,010,907 and in International Patent No. PCT/US00/23457; and in International Patent Publication Nos. WO 98/49350; WO 99/07865; WO 99/58723; WO 99/58702; and WO 99/40789.

The plant can be of any species of dicotyledonous, monocotyledonous or gymnospermous plant, including any woody plant species that grows as a tree or shrub, any herbaceous species, or any species that produces edible fruits, seeds or vegetables, or any

species that produces colorful or aromatic flowers. For example, the plant may be selected from a species of plant from the group consisting of canola, sunflower, tobacco, sugar beet, cotton, maize, wheat, barley, rice, sorghum, tomato, mango, peach, apple, pear, strawberry, banana, melon, potato, carrot, lettuce, onion, soya spp, sugar cane, pea, field beans, poplar, grape, citrus, alfalfa, rye, oats, turf and forage grasses, flax, oilseed rape, cucumber, morning glory, balsam, pepper, eggplant, marigold, lotus, cabbage, daisy, carnation, tulip, iris, lily, and nut producing plants insofar as they are not already specifically mentioned.

The recombinagenic oligonucleobase can be introduced into a plant cell using any method commonly used in the art, including but not limited to, microcarriers (biolistic delivery), microfibers, electroporation, microinjection.

The invention is also directed to the culture of cells mutated according to the methods of the present invention in order to obtain a plant that produces seeds, henceforth a "fertile plant", and the production of seeds and additional plants from such a fertile plant.

The invention is further directed to a method of selectively controlling weeds in a field, the field comprising plants with the disclosed EPSPS gene alterations and weeds, the method comprising application to the field of a herbicide to which the said plants have been rendered resistant.

The invention is also directed to novel mutations in the EPSPS gene that confer resistance or tolerance to a member of the phosphonomethylglycine family, *e.g.*, glyphosate, to a plant or wherein the mutated EPSPS has substantially the same enzymatic activity as compared to wild-type EPSPS.

3.1 DEFINITIONS

The invention is to be understood in accordance with the following definitions.

An oligonucleobase is a polymer of nucleobases, which polymer can hybridize by Watson-Crick base pairing to a DNA having the complementary sequence.

Nucleobases comprise a base, which is a purine, pyrimidine, or a derivative or analog thereof. Nucleobases include peptide nucleobases, the subunits of peptide nucleic acids, and morpholine nucleobases as well as nucleosides and nucleotides. Nucleosides are nucleobases that contain a pentosefuranosyl moiety, *e.g.*, an optionally substituted riboside or 2'-deoxyriboside. Nucleosides can be linked by one of several linkage moieties, which may or may not contain a phosphorus. Nucleosides that are linked by unsubstituted phosphodiester linkages are termed nucleotides.

An oligonucleobase chain has a single 5' and 3' terminus, which are the ultimate nucleobases of the polymer. A particular oligonucleobase chain can contain

nucleobases of all types. An oligonucleobase compound is a compound comprising one or more oligonucleobase chains that are complementary and hybridized by Watson-Crick base pairing. Nucleobases are either deoxyribo-type or ribo-type. Ribo-type nucleobases are pentosefuranosyl containing nucleobases wherein the 2' carbon is a methylene substituted
5 with a hydroxyl, alkyloxy or halogen. Deoxyribo-type nucleobases are nucleobases other than ribo-type nucleobases and include all nucleobases that do not contain a pentosefuranosyl moiety.

An oligonucleobase strand generically includes both oligonucleobase chains and segments or regions of oligonucleobase chains. An oligonucleobase strand has a 3' end
10 and a 5' end. When an oligonucleobase strand is coextensive with a chain, the 3' and 5' ends of the strand are also 3' and 5' termini of the chain.

According to the present invention, substantially normal growth of a plant, plant organ, plant tissue or plant cell is defined as a growth rate or rate of cell division of the plant, plant organ, plant tissue, or plant cell that is at least 35%, at least 50%, at least 60%,
15 or at least 75% of the growth rate or rate of cell division in a corresponding plant, plant organ, plant tissue or plant cell expressing the wild type EPSPS protein.

According to the present invention, substantially normal development of a plant, plant organ, plant tissue or plant cell is defined as the occurrence of one or more developmental events in the plant, plant organ, plant tissue or plant cell that are
20 substantially the same as those occurring in a corresponding plant, plant organ, plant tissue or plant cell expressing the wild type EPSPS protein.

According to the present invention plant organs include, but are not limited to, leaves, stems, roots, vegetative buds, floral buds, meristems, embryos, cotyledons, endosperm, sepals, petals, pistils, carpels, stamens, anthers, microspores, pollen, pollen
25 tubes, ovules, ovaries and fruits, or sections, slices or discs taken therefrom. Plant tissues include, but are not limited to, callus tissues, ground tissues, vascular tissues, storage tissues, meristematic tissues, leaf tissues, shoot tissues, root tissues, gall tissues, plant tumor tissues, and reproductive tissues. Plant cells include, but are not limited to, isolated cells with cell walls, variously sized aggregates thereof, and protoplasts.

Plants are substantially "tolerant" to glyphosate when they are subjected to it and provide a dose/response curve which is shifted to the right when compared with that provided by similarly subjected non-tolerant like plant. Such dose/response curves have "dose" plotted on the X-axis and "percentage kill", "herbicidal effect", etc., plotted on the y-axis. Tolerant plants will require more herbicide than non-tolerant like plants in order to
35 produce a given herbicidal effect. Plants which are substantially "resistant" to the glyphosate exhibit few, if any, necrotic, lytic, chlorotic or other lesions, when subjected to

glyphosate at concentrations and rates which are typically employed by the agrochemical community to kill weeds in the field. Plants which are resistant to a herbicide are also tolerant of the herbicide. The terms “resistant” and “tolerant” are to be construed as “tolerant and/or resistant” within the context of the present application.

4. BRIEF DESCRIPTION OF THE FIGURES

FIG. 1A is the DNA sequence of *Arabidopsis thaliana* EPSPS gene (SEQ ID NO:1). The bold underlined nucleotide residues are the targeted residues.

FIG. 1B is the amino acid sequence of *Arabidopsis thaliana* EPSPS protein (SEQ ID NO:2). The bold and underlined amino acid residues are the targeted residues.

FIG. 2 is a list of the *Arabidopsis thaliana* wild-type and mutant EPSPS nucleotide and amino acid sequences in the region of amino acid position 173 to 183; wild-type nucleotide sequence (SEQ ID NO:1) and wild-type amino acid sequence (SEQ ID NO:2); mutant A₁₇₇ nucleotide sequence (SEQ ID NO:3) and amino acid sequence (SEQ ID NO:4); mutant I₁₇₈ nucleotide sequence (SEQ ID NO:5) and amino acid sequence (SEQ ID NO:6); mutant A₁₇₇I₁₇₈ nucleotide sequence (SEQ ID NO:7) and amino acid sequence (SEQ ID NO:8); mutant I₁₇₈S₁₈₂ nucleotide sequence (SEQ ID NO:9) and amino acid sequence (SEQ ID NO:10); mutant A₁₇₇S₁₈₂ nucleotide sequence (SEQ ID NO:11) and amino acid sequence (SEQ ID NO:12); mutant A₁₇₇I₁₇₈S₁₈₂ nucleotide sequence (SEQ ID NO:13) and amino acid sequence (SEQ ID NO:14); mutant V₁₇₇S₁₈₂ nucleotide sequence (SEQ ID NO:15) and amino acid sequence (SEQ ID NO:16); mutant L₁₇₈S₁₈₂ nucleotide sequence (SEQ ID NO:17) and amino acid sequence (SEQ ID NO:18); mutant A₁₇₇V₁₇₈ nucleotide sequence (SEQ ID NO:19) and amino acid sequence (SEQ ID NO:20); mutant A₁₇₇L₁₈₂ nucleotide sequence (SEQ ID NO:21) and amino acid sequence (SEQ ID NO:22).

FIG. 3A-C is an alignment of the DNA of *Arabidopsis thaliana* EPSPS gene performed by DNASTar (LaserGene), (SEQ ID NO:1) with the nucleotide sequences of *Brassica napus* (SEQ ID NO:23); *Petunia hybrida* (SEQ ID NO:24); and *Zea mays* (SEQ ID NO:25) EPSPS gene. The sequences are aligned using J. Hein method with weighted residue weight table.

30

FIG. 4 is an alignment of the *Arabidopsis thaliana* EPSPS amino acid sequence (SEQ ID NO:2) with the *Brassica napus* (SEQ ID NO:26); *Petunia hybrida* (SEQ ID NO:27); and *Zea mays* (SEQ ID NO:28) EPSPS amino acid sequences. The sequences are aligned using J. Hein method with weighted residue weight table.

FIG. 5 is a list of the mutagenesis primers used, with the targeted codons in bold characters (mutant primer A₁₇₇ (SEQ ID NO:29); mutant primer I₁₇₈ (SEQ ID NO:30);

35

mutant primer A₁₇₇I₁₇₈ (SEQ ID NO:31); mutant primer I₁₇₈S₁₈₂ (SEQ ID NO:32); mutant primer A₁₇₇S₁₈₂ (SEQ ID NO:34); mutant primer A₁₇₇I₁₇₈S₁₈₂ (SEQ ID NO:35); mutant primer V₁₇₇S₁₈₂ (SEQ ID NO:35); mutant primer L₁₇₈S₁₈₂ (SEQ ID NO:36); mutant primer A₁₇₇V₁₇₈ (SEQ ID NO:37); and mutant primer A₁₇₇L₁₈₂ (SEQ ID NO:38)).

5 FIG. 6 is the growth measured by optical density at 600 nm of *Arabidopsis* clones in the presence (+) and absence (-) of 17 mM glyphosate.

FIG. 7 (top panel) is a western blot showing the expression of His-tagged *Bacillus*, *Arabidopsis* wild type (WT) and mutant (AS) EPSPS proteins isolated from cell lysates (L) and eluates (E). Untransformed *Salmonella* as a negative control shows no
10 EPSPS expression. The bottom panel is a silver-stained duplicate gel.

5. DETAILED DESCRIPTION OF THE INVENTION

The present invention is directed to a non-transgenic plant or plant cell having a mutation in the EPSPS gene, which plant has increased resistance or tolerance to a
15 member of the phosphonomethylglycine family and which plant exhibits substantially normal growth or development of the plant, its organs, tissues or cells, as compared to the corresponding wild-type plant or cell. The present invention is also directed to a non-transgenic plant having a mutation in the EPSPS gene, which plant is resistant to or has an increased tolerance to a member of the phosphonomethylglycine family, e.g., glyphosate,
20 wherein the mutated EPSPS protein has substantially the same catalytic activity as compared to the wild-type EPSPS protein.

The present invention is also directed to a method for producing a non-transgenic plant having a mutated EPSPS gene that substantially maintains the catalytic activity of the wild-type protein irrespective of the presence or absence of a herbicide of the
25 phosphonomethylglycine family. The method comprises introducing into a plant cell a recombinagenic oligonucleobase with a targeted mutation in the EPSPS gene and identifying a cell, seed, or plant having a mutated EPSPS gene.

Illustrative examples of a recombinagenic oligonucleobase is found in following patent publications, which are incorporated in their entirety by reference herein:
30 U.S. Patent Nos. 5,565,350; 5,756,325; 5,871,984; 5,760,012; 5,731,181; 5,888,983; 5,795,972; 5,780,296; 5,945,339; 6,004,804; and 6,010,907 and in International Patent No. PCT/US00/23457; and in International Patent Publication Nos. WO 98/49350; WO 99/07865; WO 99/58723; WO 99/58702; and WO 99/40789.

The plant can be of any species of dicotyledonous, monocotyledonous or
35 gymnospermous plant, including any woody plant species that grows as a tree or shrub, any herbaceous species, or any species that produces edible fruits, seeds or vegetables, or any

species that produces colorful or aromatic flowers. For example, the plant may be selected from a species of plant from the group consisting of canola, sunflower, tobacco, sugar beet, cotton, maize, wheat, barley, rice, sorghum, tomato, mango, peach, apple, pear, strawberry, banana, melon, potato, carrot, lettuce, onion, soya spp, sugar cane, pea, field beans, poplar, grape, citrus, alfalfa, rye, oats, turf and forage grasses, flax, oilseed rape, cucumber, morning glory, balsam, pepper, eggplant, marigold, lotus, cabbage, daisy, carnation, tulip, iris, lily, and nut producing plants insofar as they are not already specifically mentioned.

The recombinagenic oligonucleobase can be introduced into a plant cell using any method commonly used in the art, including but not limited to, microcarriers (biolistic delivery), microfibers, electroporation, microinjection.

The invention is also directed to the culture of cells mutated according to the methods of the present invention in order to obtain a plant that produces seeds, henceforth a "fertile plant", and the production of seeds and additional plants from such a fertile plant.

The invention is further directed to a method of selectively controlling weeds in a field, the field comprising plants with the disclosed EPSPS gene alterations and weeds, the method comprising application to the field of a herbicide to which the said plants have been rendered resistant.

The invention is also directed to novel mutations in the EPSPS gene that confer resistance or tolerance to a member of the phosphonomethylglycine family, *e.g.*, glyphosate, to a plant or wherein the mutated EPSPS has substantially the same enzymatic activity as compared to wild-type EPSPS.

5.1 RECOMBINAGENIC OLIGONUCLEOBASES

The invention can be practiced with recombinagenic oligonucleobases having the conformations and chemistries described in United States patent No. 5,565,350 to Kmiec (Kmiec I) and U.S. patent No. 5,731,181 (Kmiec II) gene, which are hereby incorporated by reference. Kmiec I teaches a method for introducing specific genetic alterations into a target gene. The recombinagenic oligonucleobases in Kmiec I and/or Kmiec II contain two complementary strands, one of which contains at least one segment of RNA-type nucleotides (an "RNA segment") that are base paired to DNA-type nucleotides of the other strand.

Kmiec II discloses that purine and pyrimidine base-containing non-nucleotides can be substituted for nucleotides. U.S. Patent Nos. 5,756,325; 5,871,984; 5,760,012; 5,888,983; 5,795,972; 5,780,296; 5,945,339; 6,004,804; and 6,010,907 and in International Patent No. PCT/US00/23457; and in International Patent Publication Nos. WO 98/49350; WO 99/07865; WO 99/58723; WO 99/58702; and WO 99/40789, which are each

hereby incorporated in their entirety, disclose additional recombinagenic molecules that can be used for the present invention. The term "recombinagenic oligonucleobase" is used herein to denote the molecules that can be used in the methods of the present invention and include mixed duplex oligonucleotides, non-nucleotide containing molecules taught in
5 Kmiec II, single stranded oligodeoxynucleotides and other recombinagenic molecules taught in the above noted patents and patent publications.

In one embodiment, the recombinagenic oligonucleobase is a mixed duplex oligonucleotide in which the RNA-type nucleotides of the mixed duplex oligonucleotide are made RNase resistant by replacing the 2'-hydroxyl with a fluoro, chloro or bromo
10 functionality or by placing a substituent on the 2'-O. Suitable substituents include the substituents taught by the Kmiec II. Alternative substituents include the substituents taught by U.S. Patent No. 5,334,711 (Sproat) and the substituents taught by patent publications EP 629 387 and EP 679 657 (collectively, the Martin Applications), which are hereby incorporated by reference. As used herein, a 2' -fluoro, chloro or bromo derivative of a
15 ribonucleotide or a ribonucleotide having a 2'-OH substituted with a substituent described in the Martin Applications or Sproat is termed a "2'-Substituted Ribonucleotide." As used herein the term "RNA-type nucleotide" means a 2'-hydroxyl or 2'-Substituted Nucleotide that is linked to other nucleotides of a mixed duplex oligonucleotide by an unsubstituted phosphodiester linkage or any of the non-natural linkages taught by Kmiec I or Kmiec II.
20 As used herein the term "deoxyribo-type nucleotide" means a nucleotide having a 2'-H, which can be linked to other nucleotides of a MDON by an unsubstituted phosphodiester linkage or any of the non-natural linkages taught by Kmiec I or Kmiec II.

In a particular embodiment of the present invention, the recombinagenic oligonucleobase is a mixed duplex oligonucleotide that is linked solely by unsubstituted
25 phosphodiester bonds. In alternative embodiments, the linkage is by substituted phosphodiesters, phosphodiester derivatives and non-phosphorus-based linkages as taught by Kmiec II. In yet another embodiment, each RNA-type nucleotide in the mixed duplex oligonucleotide is a 2'-Substituted Nucleotide. Particular preferred embodiments of 2'-Substituted Ribonucleotides are 2'-fluoro, 2'-methoxy, 2'-propyloxy, 2'-allyloxy, 2'-
30 hydroxyethyloxy, 2'-methoxyethyloxy, 2'-fluoropropyloxy and 2'-trifluoropropyloxy substituted ribonucleotides. More preferred embodiments of 2'-Substituted Ribonucleotides are 2'-fluoro, 2'-methoxy, 2'-methoxyethyloxy, and 2'-allyloxy substituted nucleotides. In another embodiment the mixed duplex oligonucleotide is linked by unsubstituted phosphodiester bonds.

35 Although mixed duplex oligonucleotide having only a single type of 2'-substituted RNA-type nucleotide are more conveniently synthesized, the methods of the

invention can be practiced with mixed duplex oligonucleotides having two or more types of RNA-type nucleotides. The function of an RNA segment may not be affected by an interruption caused by the introduction of a deoxynucleotide between two RNA-type trinucleotides, accordingly, the term RNA segment encompasses such an “interrupted RNA segment.” An uninterrupted RNA segment is termed a contiguous RNA segment. In an alternative embodiment an RNA segment can contain alternating RNase-resistant and unsubstituted 2'-OH nucleotides. The mixed duplex oligonucleotides preferably have fewer than 100 nucleotides and more preferably fewer than 85 nucleotides, but more than 50 nucleotides. The first and second strands are Watson-Crick base paired. In one embodiment the strands of the mixed duplex oligonucleotide are covalently bonded by a linker, such as a single stranded hexa, penta or tetranucleotide so that the first and second strands are segments of a single oligonucleotide chain having a single 3' and a single 5' end. The 3' and 5' ends can be protected by the addition of a “hairpin cap” whereby the 3' and 5' terminal nucleotides are Watson-Crick paired to adjacent nucleotides. A second hairpin cap can, additionally, be placed at the junction between the first and second strands distant from the 3' and 5' ends, so that the Watson-Crick pairing between the first and second strands is stabilized.

The first and second strands contain two regions that are homologous with two fragments of the target EPSPS gene, *i.e.*, have the same sequence as the target gene. A homologous region contains the nucleotides of an RNA segment and may contain one or more DNA-type nucleotides of connecting DNA segment and may also contain DNA-type nucleotides that are not within the intervening DNA segment. The two regions of homology are separated by, and each is adjacent to, a region having a sequence that differs from the sequence of the target gene, termed a “heterologous region.” The heterologous region can contain one, two or three mismatched nucleotides. The mismatched nucleotides can be contiguous or alternatively can be separated by one or two nucleotides that are homologous with the target gene. Alternatively, the heterologous region can also contain an insertion or one, two, three or of five or fewer nucleotides. Alternatively, the sequence of the mixed duplex oligonucleotide may differ from the sequence of the target gene only by the deletion of one, two, three, or five or fewer nucleotides from the mixed duplex oligonucleotide. The length and position of the heterologous region is, in this case, deemed to be the length of the deletion, even though no nucleotides of the mixed duplex oligonucleotide are within the heterologous region. The distance between the fragments of the target gene that are complementary to the two homologous regions is identically the length of the heterologous region when a substitution or substitutions is intended. When the heterologous region contains an insertion, the homologous regions are thereby separated in

the mixed duplex oligonucleotide farther than their complementary homologous fragments are in the gene, and the converse is applicable when the heterologous region encodes a deletion.

The RNA segments of the mixed duplex oligonucleotides are each a part of a homologous region, *i.e.*, a region that is identical in sequence to a fragment of the target gene, which segments together preferably contain at least 13 RNA-type nucleotides and preferably from 16 to 25 RNA-type nucleotides or yet more preferably 18-22 RNA-type nucleotides or most preferably 20 nucleotides. In one embodiment, RNA segments of the homology regions are separated by and adjacent to, *i.e.*, "connected by" an intervening DNA segment. In one embodiment, each nucleotide of the heterologous region is a nucleotide of the intervening DNA segment. An intervening DNA segment that contains the heterologous region of a mixed duplex oligonucleotide is termed a "mutator segment."

The change to be introduced into the target EPSPS gene is encoded by the heterologous region. The change to be introduced into the EPSPS gene may be a change in one or more bases of the EPSPS gene sequence or the addition or deletion of one or more bases.

In another embodiment of the present invention, the recombinagenic oligonucleobase is a single stranded oligodeoxynucleotide mutational vector or SSOMV, which is disclosed in International Patent Application PCT/US00/23457, which is incorporated by reference in its entirety. The sequence of the SSOMV is based on the same principles as the mutational vectors described in U.S. Patent Nos. 5,756,325; 5,871,984; 5,760,012; 5,888,983; 5,795,972; 5,780,296; 5,945,339; 6,004,804; and 6,010,907 and in International Publication Nos. WO 98/49350; WO 99/07865; WO 99/58723; WO 99/58702; and WO 99/40789. The sequence of the SSOMV contains two regions that are homologous with the target sequence separated by a region that contains the desired genetic alteration termed the mutator region. The mutator region can have a sequence that is the same length as the sequence that separates the homologous regions in the target sequence, but having a different sequence. Such a mutator region can cause a substitution. Alternatively, the homologous regions in the SSOMV can be contiguous to each other, while the regions in the target gene having the same sequence are separated by one, two or more nucleotides. Such a SSOMV causes a deletion from the target gene of the nucleotides that are absent from the SSOMV. Lastly, the sequence of the target gene that is identical to the homologous regions may be adjacent in the target gene but separated by one two or more nucleotides in the sequence of the SSOMV. Such an SSOMV causes an insertion in the sequence of target gene.

The nucleotides of the SSOMV are deoxyribonucleotides that are linked by unmodified phosphodiester bonds except that the 3' terminal and/or 5' terminal internucleotide linkage or alternatively the two 3' terminal and/or 5' terminal internucleotide linkages can be a phosphorothioate or phosphoamidate. As used herein an internucleotide linkage is the linkage between nucleotides of the SSOMV and does not include the linkage between the 3' end nucleotide or 5' end nucleotide and a blocking substituent, see *supra*. In a specific embodiment the length of the SSOMV is between 21 and 55 deoxynucleotides and the lengths of the homology regions are, accordingly, a total length of at least 20 deoxynucleotides and at least two homology regions should each have lengths of at least 8 deoxynucleotides.

The SSOMV can be designed to be complementary to either the coding or the non-coding strand of the target gene. When the desired mutation is a substitution of a single base, it is preferred that both the mutator nucleotide be a pyrimidine. To the extent that is consistent with achieving the desired functional result it is preferred that both the mutator nucleotide and the targeted nucleotide in the complementary strand be pyrimidines. Particularly preferred are SSOMV that encode transversion mutations, *i.e.*, a C or T mutator nucleotide is mismatched, respectively, with a C or T nucleotide in the complementary strand.

In addition to the oligodeoxynucleotide the SSOMV can contain a 5' blocking substituent that is attached to the 5' terminal carbons through a linker. The chemistry of the linker is not critical other than its length, which should preferably be at least 6 atoms long and that the linker should be flexible. A variety of non-toxic substituents such as biotin, cholesterol or other steroids or a non-intercalating cationic fluorescent dye can be used. Particularly preferred as reagents to make SSOMV are the reagents sold as Cy3™ and Cy5™ by Glen Research, Sterling VA, which are blocked phosphoramidites that upon incorporation into an oligonucleotide yield 3,3',3'-tetramethyl N,N'-isopropyl substituted indomonocarbocyanine and indodicarbocyanine dyes, respectively. Cy3 is the most preferred. When the indocarbocyanine is N-oxyalkyl substituted it can be conveniently linked to the 5' terminal of the oligodeoxynucleotide through as a phosphodiester with a 5' terminal phosphate. The chemistry of the dye linker between the dye and the oligodeoxynucleotide is not critical and is chosen for synthetic convenience. When the commercially available Cy3 phosphoramidite is used as directed the resulting 5' modification consists of a blocking substituent and linker together which are a N-hydroxypropyl, N'-phosphatidylpropyl 3,3',3'-tetramethyl indomonocarbocyanine.

In the preferred embodiment the indocarbocyanine dye is tetra substituted at the 3 and 3' positions of the indole rings. Without limitation as to theory these substitutions

prevent the dye from being an intercalating dye. The identity of the substituents at these positions are not critical. The SSOMV can in addition have a 3' blocking substituent. Again the chemistry of the 3' blocking substituent is not critical.

5 5.2 THE LOCATION AND TYPE OF MUTATION
INTRODUCED INTO THE EPSPS GENE

In one embodiment of the present invention, the *Arabidopsis thaliana* EPSPS gene (see Figure 1A) and corresponding EPSPS enzyme (see Figure 1B) comprises a mutation at one or more amino acid residues selected from the group consisting of Leu₁₇₃, Gly₁₇₇, Thr₁₇₈, Ala₁₇₉, Met₁₈₀, Arg₁₈₁, Pro₁₈₂, Ser₉₈, Ser₂₅₅ and Leu₁₉₈, or at an analogous position in an EPSPS paralog, and the mutation results in one or more of the following amino acid substitutions in the EPSPS enzyme in comparison with the wild-type sequence:

- (i) Leu₁₇₃ - Phe
- (ii) Gly₁₇₇ - Ala or Ile
- 15 (iii) Thr₁₇₈ - Ile or Val or Leu
- (iv) Ala₁₇₉ - Gly
- (v) Met₁₈₀ - Cys
- (vi) Arg₁₈₁ - Leu or Ser
- (vii) Pro₁₈₂ - Leu or Ser
- 20 (viii) Ser₉₈ -Asp
- (ix) Ser₂₅₅ -Ala
- (x) Leu₁₉₈ -Lys.

In another embodiment of the present invention, within the EPSPS gene product, the amino acid residue to be changed is Leu within the contiguous sequence Leu-Tyr-Leu-Gly-Asn (SEQ ID NO:29) and is changed to Phe; or the amino acid residue to be changed is Gly within the contiguous sequence Asn-Ala-Gly-Thr-Ala (SEQ ID NO:30) and is changed to Ala or Ile; or the amino acid to be changed is Thr within the contiguous sequence Ala-Gly-Thr-Ala-Met (SEQ ID NO:31) and is changed to Ile, Val or Leu; or the amino acid to be changed is Ala within the contiguous sequence Gly-Thr-Ala-Met-Arg (SEQ ID NO:32) and is changed to Gly; or the amino acid to be changed is Met within the contiguous sequence Thr-Ala-Met-Arg-Pro (SEQ ID NO:33) and is changed to Cys; or the amino acid to be changed is Arg within the contiguous sequence Ala-Met-Arg-Pro-Leu (SEQ ID NO:34) and is changed to Leu or Ser; or the amino acid to be changed is Pro within the contiguous sequence Met-Arg-Pro-Leu-Thr (SEQ ID NO:35) and is changed to Leu or Ser; or the amino acid to be changed is Ser within a contiguous Pro-Gly-Ser-Lys-Ser (SEQ ID NO:36) and is changed to Asp; or the amino acid to be changed is Ser within the

contiguous sequence Ile-Ser-Ser-Gln-Tyr (SEQ ID NO:37) and is changed to Ala; or the amino acid to be changed is Leu within the contiguous sequence Tyr-Val-Leu-Asp-Gly (SEQ ID NO:38) and is changed to Lys. In other embodiments, one or more of the foregoing changes can be made in the EPSPS amino acid sequence.

5 Alternatively, and/or additionally, the mutation may result in the replacement of any amino acid at positions corresponding to 256, 284-288 and 353-356 with respect to the EPSPS protein depicted in Figure 1B (SEQ ID NO. 2).

In specific embodiments of the present invention, the EPSPS gene is mutated at amino acid position 177 in which Gly is replaced by Ala. Another specific embodiment
10 is the substitution of Thr at amino acid position 178 by Ile. A further specific embodiment comprises a mutation at amino acid position 177 in which Gly is replaced by Ala, plus the additional substitution of Thr at amino acid position 178 by Ile. Other specific embodiments of the present invention are directed to mutations at amino acid position 178, in which Thr is replaced by Ile, plus the additional mutation at position 182, in which Pro is
15 replaced by Ser. Other embodiments include the substitution of Gly at amino acid position 177 by Ala, plus the additional mutation at amino acid position 182, in which Pro is substituted by Ser. Other mutated EPSPS sequences comprise the substitution of Gly at position 177 by Ala, plus the substitution at position 178, in which Thr is replaced by Ile, plus the additional substitution of Pro at amino acid position 182 by Ser. Another
20 embodiment is the substitution of Thr at amino acid position 178 by Val and the additional mutation at amino acid position 182, in which Pro is replaced by Ser. A further specific embodiment includes the substitution of Thr at position 178 by Leu, plus the mutation at amino acid position 182, in which Pro is replaced by Ser. A further embodiment includes, the substitution at amino acid position 177 in which Gly is replaced by Ala, plus the
25 substitution of Thr at position 178 by Val. The invention also embodies the substitution at amino acid position 177 in which Gly is replaced by Ala, plus the replacement of Thr at amino acid position 178 by Leu (see Figure 2).

The foregoing mutations in the EPSPS gene were described using the *Arabidopsis thaliana* EPSPS gene (SEQ ID NO:1) and protein (SEQ ID NO:2). The
30 present invention also encompasses mutant EPSPS genes of other species (paralogs). However, due to variations in the EPSPS genes of different species, the number of the amino acid residue to be changed in one species may be different in another species. Nevertheless, the analogous position is readily identified by one of skill in the art by sequence homology. For example, Figure 3A-C shows the aligned nucleotide sequences
35 and Figure 4 shows the aligned amino acid sequences of four paralogs of the EPSPS gene, *Arabidopsis thaliana*, *Zea mays*, *Petunia hybrida*, and *Brassica napus*. Thus, the analogous

positions in *Zea mays* are Leu₉₇, Gly₁₀₁, Thr₁₀₂, Ala₁₀₃, Met₁₀₄, Arg₁₀₅, Pro₁₀₆, Ser₂₃, Ser₁₇₉ and Leu₁₂₂. Thus, the *Zea mays* EPSPS amino acid sequence is mutated at one or more of the following amino acid positions and results in one or more of the following substitutions:

- (i) Leu₉₇ - Phe
- 5 (ii) Gly₁₀₁ - Ala or Ile
- (iii) Thr₁₀₂ - Ile or Val or Leu
- (iv) Ala₁₀₃ - Gly
- (v) Met₁₀₄ - Cys
- (vi) Arg₁₀₅ - Leu or Ser
- 10 (vii) Pro₁₀₆ - Leu or Ser
- (viii) Ser₂₃ -Asp
- (ix) Ser₁₇₉ -Ala
- (x) Leu₁₂₂ -Lys.

In another embodiment of the present invention, within the *Zea mays* EPSPS gene product the amino acid residue to be changed is Leu within the contiguous sequence Leu-Phe-Leu-Gly-Asn (SEQ ID NO:39) and is changed to Phe; or the amino acid residue to be changed is Gly within the contiguous sequence Asn-Ala-Gly-Thr-Ala (SEQ ID NO:30) and is changed to Ala or Ile; or the amino acid to be changed is Thr within the contiguous sequence Ala-Gly-Thr-Ala-Met (SEQ ID NO:31) and is changed to Ile, Val or Leu; or the amino acid to be changed is Ala within the contiguous sequence Gly-Thr-Ala-Met-Arg (SEQ ID NO:32) and is changed to Gly; or the amino acid to be changed is Met within the contiguous sequence Thr-Ala-Met-Arg-Pro (SEQ ID NO:33) and is changed to Cys; or the amino acid to be changed is Arg within the contiguous sequence Ala-Met-Arg-Pro-Leu (SEQ ID NO:34) and is changed to Leu or Ser; or the amino acid to be changed is Pro within the contiguous sequence Met-Arg-Pro-Leu-Thr (SEQ ID NO:35) and is changed to Leu or Ser; or the amino acid to be changed is Ser within a contiguous Pro-Gly-Ser-Lys-Ser (SEQ ID NO:36) and is changed to Asp; or the amino acid to be changed is Ser within the contiguous sequence Ile-Ser-Ser-Gln-Tyr (SEQ ID NO:37) and is changed to Ala; or the amino acid to be changed is Leu within the contiguous sequence Tyr-Val-Leu-Asp-Gly (SEQ ID NO:38) and is changed to Lys. In other embodiments, one or more of the foregoing changes can be made in the EPSPS amino acid sequence.

In *Brassica napus*, the analogous amino acid positions are Leu₁₆₉, Gly₁₇₃, Thr₁₇₄, Ala₁₇₅, Met₁₇₆, Arg₁₇₇, Pro₁₇₈, Ser₉₄, Ser₂₅₁ and Leu₁₉₄. Thus, the *Brassica napus* EPSPS amino acid sequence is mutated at one or more of the following amino acid positions and results in one or more of the following substitutions:

- (i) Leu₁₆₉ - Phe

- (ii) Gly₁₇₃ - Ala or Ile
- (iii) Thr₁₇₄ - Ile or Val or Leu
- (iv) Ala₁₇₅ - Gly
- (v) Met₁₇₆ - Cys
- (vi) Arg₁₇₇ - Leu or Ser
- (vii) Pro₁₇₈ - Leu or Ser
- (viii) Ser₉₄ -Asp
- (ix) Ser₂₅₁ -Ala
- (x) Leu₁₉₄ -Lys

5

10

15

20

25

In another embodiment of the present invention, within the *Brassica napus* EPSPS gene product the amino acid residue to be changed is Leu within the contiguous sequence Leu-Tyr-Leu-Gly-Asn (SEQ ID NO:29) and is changed to Phe; or the amino acid residue to be changed is Gly within the contiguous sequence Asn-Ala-Gly-Thr-Ala (SEQ ID NO:30) and is changed to Ala or Ile; or the amino acid to be changed is Thr within the contiguous sequence Ala-Gly-Thr-Ala-Met (SEQ ID NO:31) and is changed to Ile, Val or Leu; or the amino acid to be changed is Ala within the contiguous sequence Gly-Thr-Ala-Met-Arg (SEQ ID NO:32) and is changed to Gly; or the amino acid to be changed is Met within the contiguous sequence Thr-Ala-Met-Arg-Pro (SEQ ID NO:33) and is changed to Cys; or the amino acid to be changed is Arg within the contiguous sequence Ala-Met-Arg-Pro-Leu (SEQ ID NO:34) and is changed to Leu or Ser; or the amino acid to be changed is Pro within the contiguous sequence Met-Arg-Pro-Leu-Thr (SEQ ID NO:35) and is changed to Leu or Ser; or the amino acid to be changed is Ser within a contiguous Pro-Gly-Ser-Lys-Ser (SEQ ID NO:36) and is changed to Asp; or the amino acid to be changed is Ser within the contiguous sequence Ile-Ser-Ser-Gln-Tyr (SEQ ID NO:37) and is changed to Ala; or the amino acid to be changed is Leu within the contiguous sequence Tyr-Val-Leu-Asp-Gly (SEQ ID NO:38) and is changed to Lys. In other embodiments, one or more of the foregoing changes can be made in the EPSPS amino acid sequence.

30

In *Petunia hybrida* the analogous positions are Leu₁₆₉, Gly₁₇₃, Thr₁₇₄, Ala₁₇₅, Met₁₇₆, Arg₁₇₇, Pro₁₇₈, Ser₉₄, Ser₂₅₁ and Leu₁₉₄. Thus, the *Petunia hybrida* EPSPS amino acid sequence is mutated at one or more of the following amino acid positions and results in one or more of the following substitutions:

- (i) Leu₁₆₉ - Phe
- (ii) Gly₁₇₃ - Ala or Ile
- (iii) Thr₁₇₄ - Ile or Val or Leu
- (iv) Ala₁₇₅ - Gly
- (v) Met₁₇₆ - Cys

35

- (vi) Arg₁₇₇ - Leu or Ser
- (vii) Pro₁₇₈ - Leu or Ser
- (viii) Ser₉₄ -Asp
- (ix) Ser₂₅₁ -Ala
- (x) Leu₁₉₄ -Lys

5

In another embodiment of the present invention, within the *Petunia hybrida* EPSPS gene product the amino acid residue to be changed is Leu within the contiguous sequence Leu-Phe-Leu-Gly-Asn (SEQ ID NO:39) and is changed to Phe; or the amino acid residue to be changed is Gly within the contiguous sequence Asn-Ala-Gly-Thr-Ala (SEQ ID NO:30) and is changed to Ala or Ile; or the amino acid to be changed is Thr within the contiguous sequence Ala-Gly-Thr-Ala-Met (SEQ ID NO:31) and is changed to Ile, Val or Leu; or the amino acid to be changed is Ala within the contiguous sequence Gly-Thr-Ala-Met-Arg (SEQ ID NO:32) and is changed to Gly; or the amino acid to be changed is Met within the contiguous sequence Thr-Ala-Met-Arg-Pro (SEQ ID NO:33) and is changed to Cys; or the amino acid to be changed is Arg within the contiguous sequence Ala-Met-Arg-Pro-Leu (SEQ ID NO:34) and is changed to Leu or Ser; or the amino acid to be changed is Pro within the contiguous sequence Met-Arg-Pro-Leu-Thr (SEQ ID NO:35) and is changed to Leu or Ser; or the amino acid to be changed is Ser within a contiguous Pro-Gly-Ser-Lys-Ser (SEQ ID NO:36) and is changed to Asp; or the amino acid to be changed is Ser within the contiguous sequence Ile-Ser-Ser-Gln-Tyr (SEQ ID NO:37) and is changed to Ala; or the amino acid to be changed is Leu within the contiguous sequence Tyr-Val-Leu-Asp-Gly (SEQ ID NO:38) and is changed to Lys. In other embodiments, one or more of the foregoing changes can be made in the EPSPS amino acid sequence.

25

5.3 THE DELIVERY OF RECOMBINAGENIC OLIGONUCLEOBASES INTO PLANT CELLS

30

Any commonly known method can be used in the methods of the present invention to transform a plant cell with a recombinagenic oligonucleobases. Illustrative methods are listed below.

5.3.1 MICROCARRIERS AND MICROFIBERS

35

The use of metallic microcarriers (microspheres) for introducing large fragments of DNA into plant cells having cellulose cell walls by projectile penetration is well known to those skilled in the relevant art (henceforth biolistic delivery). United States Patent Nos. 4,945,050; 5,100,792 and 5,204,253 describe general techniques for selecting microcarriers and devices for projecting them.

Specific conditions for using microcarriers in the methods of the present invention are described in International Publication WO 99/07865. In an illustrative technique, ice cold microcarriers (60 mg/ml), mixed duplex oligonucleotide (60 mg/ml) 2.5 M CaCl₂ and 0.1 M spermidine are added in that order; the mixture gently agitated, *e.g.*, by vortexing, for 10 minutes and let stand at room temperature for 10 minutes, whereupon the microcarriers are diluted in 5 volumes of ethanol, centrifuged and resuspended in 100% ethanol. Good results can be obtained with a concentration in the adhering solution of 8-10 µg/µl microcarriers, 14-17 µg/ml mixed duplex oligonucleotide, 1.1-1.4 M CaCl₂ and 18-22 mM spermidine. Optimal results were observed under the conditions of 8 µg/µl microcarriers, 16.5 µg/ml mixed duplex oligonucleotide, 1.3 M CaCl₂ and 21 mM spermidine.

Recombinagenic oligonucleobases can also be introduced into plant cells for the practice of the present invention using microfibers to penetrate the cell wall and cell membrane. U.S. Patent No. 5,302,523 to Coffee et al. describes the use of 30 x 0.5 µm and 10 x 0.3 µm silicon carbide fibers to facilitate transformation of suspension maize cultures of Black Mexican Sweet. Any mechanical technique that can be used to introduce DNA for transformation of a plant cell using microfibers can be used to deliver recombinagenic oligonucleobases for transmutation.

An illustrative technique for microfiber delivery of a recombinagenic oligonucleobase is as follows: Sterile microfibers (2 µg) are suspended in 150 µl of plant culture medium containing about 10 µg of a mixed duplex oligonucleotide. A suspension culture is allowed to settle and equal volumes of packed cells and the sterile fiber/nucleotide suspension are vortexed for 10 minutes and plated. Selective media are applied immediately or with a delay of up to about 120 hours as is appropriate for the particular trait.

5.3.2 PROTOPLAST ELECTROPORATION

In an alternative embodiment, the recombinagenic oligonucleobases can be delivered to the plant cell by electroporation of a protoplast derived from a plant part. The protoplasts are formed by enzymatic treatment of a plant part, particularly a leaf, according to techniques well known to those skilled in the art. *See, e.g.*, Gallois et al., 1996, in *Methods in Molecular Biology* 55:89-107, Humana Press, Totowa, NJ; Kipp et al., 1999, in *Methods in Molecular Biology* 133:213-221, Humana Press, Totowa, NJ. The protoplasts need not be cultured in growth media prior to electroporation. Illustrative conditions for electroporation are 3 x 10⁵ protoplasts in a total volume of 0.3 ml with a concentration of recombinagenic oligonucleobase of between 0.6 - 4 µg/mL.

5.3.3 WHISKERS AND MICROINJECTION

In yet another alternative embodiment, the recombinagenic oligonucleobase can be delivered to the plant cell by whiskers or microinjection of the plant cell. The so called whiskers technique is performed essentially as described in Frame et al., 1994, Plant J. 6:941-948. The recombinagenic oligonucleobase is added to the whiskers and used to transform the plant cells. The recombinagenic oligonucleobase may be co-incubated with plasmids comprising sequences encoding proteins capable of forming recombinase complexes in plant cells such that recombination is catalyzed between the oligonucleotide and the target sequence in the EPSPS gene.

5.4 SELECTION OF GLYPHOSATE RESISTANT PLANTS

Plants or plant cells can be tested for resistance or tolerance to a herbicide using commonly known methods in the art, e.g., by growing the plant or plant cell in the presence of a herbicide and measuring the rate of growth as compared to the growth rate in the absence of the herbicide.

6. EXAMPLE

The following experiments demonstrate the production of mutant *Arabidopsis thaliana* EPSPS genes which are resistant to the herbicide glyphosate and which allows the plant cells to maintain a growth rate

6.1 MATERIAL AND METHODS

6.1.1 ISOLATION OF *ARABIDOPSIS THALIANA* EPSPS cDNA

A 1.3 kb DNA fragment was amplified by PCR from an *Arabidopsis* cDNA library using the primers AtEXPEXP1 and AtEXPEXP2CM-2. The two primers were designed to amplify the cDNA from the mature peptide to the termination codon. The 5' primer AtEXPEXP1 contains an XbaI site (underlined) and the 3' primer AtEXPEXP2CM-2 contains a BglII site (underlined), sites which will be of use for cloning of the fragment into the expression vector.

AtEXPEXP1

5'-GCTCTAGAGAAAGCGTCGGAGATTGTACTT-3' (SEQ ID NO:40)

AtEXPEXP2CM-2

5'-GCAGATCTGAGCTCTTAGTGCTTTGTGATTCTTTCAAGTAC-3' (SEQ ID NO:41)

The PCR band was excised from the agarose gel and purified (GeneClean, Biol). Its sequence was then confirmed as the mature peptide sequence of *Arabidopsis thaliana* EPSPS gene.

5 6.1.2 PREPARATION OF THE EXPRESSION VECTOR

The EPSPS coding region of the *AroE Bacillus subtilis* gene was obtained by PCR using the following primers:

BsAroE5'Xba

5'-GCGTCTAGAAAAACGAGATAAGGTGCAG-3' (SEQ ID NO:42) and

10

BsAroE3'BamHI

5'-GCGGATCCTCAGGATTTTTTCGAAAGCTTATTAAATG-3' (SEQ ID NO:43).

15 The PCR fragment, lacking an initiation codon (ATG), was cloned in-frame to the pACLacIMH6RecA vector by replacing the ORF of *RecA* by digesting with XbaI and BamHI. pACLacIMH6RecA contained the LacI region of Pet21 at positions 1440 to 3176, the MH6 *RecA* at positions 3809 to 5188, chloramphenicol resistance gene at positions 5445-218 (5446 to 5885 and 1 to 218), and the p15A origin of replication at positions 581
20 to 1424. The coding region of *RecA* gene was cloned from *E.coli* in-frame with the start codon and 6 histidine linker (MH6) behind the LacZ promoter of pUC19.

6.1.3 CLONING OF THE ARABIDOPSIS EPSPS GENE INTO BACTERIAL EXPRESSION VECTOR

25 The *Arabidopsis* 1.3 kb PCR fragment was digested with XbaI and BamHI (compatible with BglII) and cloned into the plasmid pACYCLacIMH6EPSPS, in place of the *Bacillus* gene.

 The clones obtained (selected on chloramphenicol) were then sequenced and confirmed positive. One of the confirmed clones (pAtEPS-12) was selected and
30 junctions between the cDNA and the cloning plasmid were also confirmed to be identical to the expected sequences.

6.1.4 NOVEL POINT MUTATIONS IN THE EPSPS GENE

35 Ten different mutants of the *Arabidopsis thaliana* EPSPS gene were designed, (see Figure 2). For the mutagenesis experiments, PCR primers were designed with one, two or three mutations. The PCR reactions were performed using a regular

flanking primer (5'ATEPS-198: 5'- GAAAGCGTCGGAGATTGTAC-3' (SEQ ID NO:44)) and one of the mutation-carrying primers (see Figure 5).

The 353bp PCR fragments obtained were purified (Qiagen PCR Purification kit) and their sequence confirmed. The fragments were then digested with PstI (underlined in the primer sequences) and BamHI and ligated to the pATEPS-12 vector, which had itself been previously digested with PstI and BamHI. JM109 (Promega) competent cells were used for the transformation and plated onto chloramphenicol-containing LB plates. Clones from each mutagenesis experiment were then isolated and their sequence confirmed.

6.1.5 GLYPHOSATE RESISTANCE ASSAYS

Electrocompetent cells of SA4247, a LacZ - *Salmonella typhi* strain, were prepared according to well known procedures (see Current Protocols in Molecular Biology, (Wiley and Sons, Inc.)). 30 μ l of SA4247 competent cells were electroporated with 20 ng of each plasmid DNA encoding *Arabidopsis* wild-type and mutant EPSPS proteins, *Bacillus* wild-type EPSPS, along with a mock transfection as a control. The settings for electroporation were 25 μ F, 2.5KV and 200 ohms. After electroporation, the cells were transferred into 15 mls culture tube and supplemented with 970 μ l of SOC medium. The cultures were incubated for 1 1/2 hours at 37°C at 225 rpm. 50 μ l of each culture were plated onto LB plates containing 17 μ g/ml chloramphenicol (in duplicates) and incubated overnight at 37°C. On the following day, 5 colonies of each plate were picked and transferred onto M9 plates and incubated overnight at 37°C.

Colonies from the overnight incubation on solid M9 were inoculated into 4 ml of liquid M9 medium and grown overnight at 37°C. On the following day, 25 ml of liquid M9 medium containing chloramphenicol, IPTG and 17 mM or 0 mM Glyphosate (Aldrich, 33775-7) were inoculated with 1-2 mls of each overnight culture (in duplicates), the starting OD (at 600 nm) was measured and all the cultures were normalized to start at the same OD. An OD measurement was taken every hour for seven hours. As a control of the bacterial growth, a culture of untransformed *Salmonella* was also inoculated into plain LB medium. In two independent experiments, the clones A₁₇₇I₁₇₈, A₁₇₇V₁₇₈, A₁₇₇L₁₇₈ and I₁₇₇ did not grow in M9 medium, therefore the glyphosate-resistance assays could not be performed on them.

6.1.7 ISOLATION AND PURIFICATION OF THE EXPRESSED PROTEIN FROM BACTERIAL CLONES

One milliliter of overnight culture of each of the bacterial clones is inoculated into 100 ml of liquid LB medium containing chloramphenicol. The cells were

allowed to grow at 37°C until they reached an OD of 0.5-0.7 (approximately 3 ½ hours). IPTG was then added to the cultures to a concentration of 1.0 mM. The cells were grown five additional hours. They were then pelleted at 4000 rpm for 20 minutes at 4°C.

The isolation and the purification of the His-tagged proteins were performed following the Qiagen Ni-NTA Protein Purification System. Cell lysates and eluates were run in duplicates on 12.5% acrylamide gels. One of the gels was silver-stained for immediate visualization, the second gel was transferred onto Millipore Immobilon-P membrane, and blocked overnight in 5% milk in TBS-T. The membrane was then exposed to Anti-His primary antibody solution (Amersham Pharmacia biotech, cat# 37-4710), followed by exposure to Anti-Mouse-IgG secondary antibody solution. (NIF825, from Amersham Pharmacia biotech ECL Western blotting analysis system, cat# RPN2108). Washes and detection reactions were performed according to the manufacturer instructions. Autoradiograms were developed after 5 minutes exposure.

6.2 RESULTS

Cells containing a mutation in the EPSPS gene produced cells that were both resistant to the herbicide glyphosate and that had a substantially similar growth rate in the absence or presence of glyphosate, as compared to the wild-type cells, irrespective of the presence of glyphosate (see Figure 6).

It was also demonstrated that the *Arabidopsis* clones containing a mutant EPSPS gene expressed the mutant protein at substantially the same level as the wild-type protein (see Figure 7).

The invention claimed and described herein is not to be limited in scope by the specific embodiments, including but not limited to the deposited microorganism embodiments, herein disclosed since these embodiments are intended as illustrations of several aspects of the invention. Indeed, various modifications of the invention in addition to those shown and described herein will become apparent to those skilled in the art from the foregoing description. Such modifications are also intended to fall within the scope of the appended claims.

A number of references are cited herein, the entire disclosures of which are incorporated herein, in their entirety, by reference.

WE CLAIM:

1. A non-transgenic herbicide resistant plant, which plant expresses a mutant EPSPS gene product and which plant has substantially normal growth as compared to a
5 plant expressing the wild-type EPSPS gene product.
2. A non-transgenic herbicide resistant plant, which plant expresses a mutant EPSPS gene product, which gene product has substantially the same level of catalytic activity as compared to the wild-type gene product.
10
3. The plant according to claim 1 or 2 in which the herbicide is a member of the phosphonomethylglycine family.
4. The plant according to claim 3 in which the member of the
15 phosphonomethylglycine family is glyphosate.
5. The plant according to claim 1 or 2 in which the EPSPS gene is mutated at one or more amino acid positions, said positions selected from the group consisting of Leu₁₇₃, Gly₁₇₇, Thr₁₇₈, Ala₁₇₉, Met₁₈₀, Arg₁₈₁, Pro₁₈₂, Ser₉₈, Ser₂₅₅ and Leu₁₉₈ in *Arabidopsis* or
20 at an analogous amino acid residue in an EPSPS paralog.
6. The plant according to claim 5 in which the positions in the *Zea mays* paralog are selected from the group consisting of Leu₉₇, Gly₁₀₁, Thr₁₀₂, Ala₁₀₃, Met₁₀₄, Arg₁₀₅, Pro₁₀₆, Ser₂₃, Ser₁₇₉ and Leu₁₂₂.
25
7. The plant according to claim 5 in which the positions in the *Brassica napus* paralog are selected from the group consisting of Leu₁₆₉, Gly₁₇₃, Thr₁₇₄, Ala₁₇₅, Met₁₇₆, Arg₁₇₇, Pro₁₇₈, Ser₉₄, Ser₂₅₁ and Leu₁₉₄.
- 30 8. The plant according to claim 5 in which the positions in the *Petunia hybrida* are selected from the group consisting of Leu₁₆₉, Gly₁₇₃, Thr₁₇₄, Ala₁₇₅, Met₁₇₆, Arg₁₇₇, Pro₁₇₈, Ser₉₄, Ser₂₅₁ and Leu₁₉₄.
9. The plant according to claim 1 or 2 in which the plant is selected from the
35 group consisting of corn, wheat, rice, barley, soybean, cotton, sugarbeet, oilseed rape,

canola, flax, sunflower, potato, tobacco, tomato, alfalfa, poplar, pine, eukalyptus, apple, lettuce, peas, lentils, grape and turf grasses.

10. The plant according to claim 5 in which the mutated gene results in one or more of the following amino acid substitutions in the EPSPS enzyme in comparison with the wild-type sequence:

- (i) Leu₁₇₃ - Phe
- (ii) Gly₁₇₇ - Ala or Ile
- (iii) Thr₁₇₈ - Ile or Val or Leu
- 10 (iv) Ala₁₇₉ - Gly
- (v) Met₁₈₀ - Cys
- (vi) Arg₁₈₁ - Leu or Ser
- (vii) Pro₁₈₂ - Leu or Ser
- (viii) Ser₉₈ - Asp
- 15 (ix) Ser₂₅₅ - Ala
- (x) Leu₁₉₈ - Lys.

11. The plant according to claim 6 in which the mutated gene results in one or more of the following amino acid substitutions in the EPSPS enzyme in comparison with the wild-type sequence:

- (i) Leu₉₇ - Phe
- (ii) Gly₁₀₁ - Ala or Ile
- (iii) Thr₁₀₂ - Ile or Val or Leu
- (iv) Ala₁₀₃ - Gly
- 25 (v) Met₁₀₄ - Cys
- (vi) Arg₁₀₅ - Leu or Ser
- (vii) Pro₁₀₆ - Leu or Ser
- (viii) Ser₂₃ - Asp
- (ix) Ser₁₇₉ - Ala
- 30 (x) Leu₁₂₂ - Lys.

12. The plant according to claim 7 in which the mutated gene results in one or more of the following amino acid substitutions in the EPSPS enzyme in comparison with the wild-type sequence:

- 35 (i) Leu₁₆₉ - Phe
- (ii) Gly₁₇₃ - Ala or Ile

- (iii) Thr₁₇₄ - Ile or Val or Leu
- (iv) Ala₁₇₅ - Gly
- (v) Met₁₇₆ - Cys
- (vi) Arg₁₇₇ - Leu or Ser
- 5 (vii) Pro₁₇₈ - Leu or Ser
- (viii) Ser₉₄ -Asp
- (ix) Ser₂₅₁ -Ala
- (x) Leu₁₉₄ -Lys.

10 13. The plant according to claim 8 in which the mutated gene results in one or more of the following amino acid substitutions in the EPSPS enzyme in comparison with the wild-type sequence:

- (i) Leu₁₆₉ - Phe
- (ii) Gly₁₇₃ - Ala or Ile
- 15 (iii) Thr₁₇₄ - Ile or Val or Leu
- (iv) Ala₁₇₅ - Gly
- (v) Met₁₇₆ - Cys
- (vi) Arg₁₇₇ - Leu or Ser
- (vii) Pro₁₇₈ - Leu or Ser
- 20 (viii) Ser₉₄ -Asp
- (ix) Ser₂₅₁ -Ala
- (x) Leu₁₉₄ -Lys.

25 14. A method for producing a non-transgenic herbicide resistant or tolerant plant comprising

- a. introducing into a plant cell a recombinagenic oligonucleobase to produce a mutant EPSPS gene; and
- b. identifying a cell having a mutated EPSPS gene, which cell has substantially normal growth as compared to a corresponding wild-type plant cell.

30

15. A method for producing a non-transgenic herbicide resistant or tolerant plant comprising

- a. introducing into a plant cell a recombinagenic oligonucleobase to produce a mutant EPSPS gene; and

35

b. identifying a cell having a mutated EPSPS gene, which encoded mutant EPSPS protein has substantially the same catalytic activity as compared to a corresponding wild-type EPSPS protein.

5 16. The method according to claim 14 or 15 in which the recombinagenic oligonucleobase is a mixed duplex nucleotide or a SSMOV.

10 17. The method according to claim 16 in which the mixed duplex nucleotide contains a first homologous region which has a sequence identical to the sequence of at least 6 base pairs of the first fragment of the target EPSPS gene and a second homologous region which has a sequence identical to the sequence of at least 6 based pairs of a second fragment of the target EPSPS gene, and an intervening region which contains at least one nucleobase heterologous to the target EPSPS gene, which intervening region connects the first and second homologous region.

15 18. The method according to claim 14 or 15 in which the recombinagenic oligonucleobase is introduced by electroporation.

20 19. The method according to claim 14 or 15 which the mutant EPSPS gene is mutated at one or more amino acid positions, said positions selected from the group consisting of Leu₁₇₃, Gly₁₇₇, Thr₁₇₈, Ala₁₇₉, Met₁₈₀, Arg₁₈₁, Pro₁₈₂, Ser₉₈, Ser₂₅₅ and Leu₁₉₈ in *Arabidopsis* or at an analogous amino acid residue in an EPSPS paralog.

25 20. The plant according to claim 19 in which the positions in the *Zea mays* paralog are selected from the group consisting of Leu₉₇, Gly₁₀₁, Thr₁₀₂, Ala₁₀₃, Met₁₀₄, Arg₁₀₅, Pro₁₀₆, Ser₂₃, Ser₁₇₉ and Leu₁₂₂.

30 21. The plant according to claim 19 in which the positions in the *Brassica napus* paralog are selected from the group consisting of Leu₁₆₉, Gly₁₇₃, Thr₁₇₄, Ala₁₇₅, Met₁₇₆, Arg₁₇₇, Pro₁₇₈, Ser₉₄, Ser₂₅₁ and Leu₁₉₄.

35 22. The plant according to claim 19 in which the positions in the *Petunia hybrida* are selected from the group consisting of Leu₁₆₉, Gly₁₇₃, Thr₁₇₄, Ala₁₇₅, Met₁₇₆, Arg₁₇₇, Pro₁₇₈, Ser₉₄, Ser₂₅₁ and Leu₁₉₄.

23. The plant according to claim 14 or 15 in which the plant is selected from the group consisting of corn, wheat, rice, barley, soybean, cotton, sugarbeet, oilseed rape, canola, flax, sunflower, potato, tobacco, tomato, alfalfa, poplar, pine, eukalyptus, apple, lettuce, peas, lentils, grape, turf grasses and *Brassica* sp.

5

24. An isolated mutant EPSPS protein comprising the amino acid sequence depicted in SEQ ID NO:2, in which amino acid position Leu₁₇₃ is replaced with Phe, Gly₁₇₇ is replaced with Ala or Ile, Thr₁₇₈ is replaced with Ile or Val or Leu, Ala₁₇₉ is replaced with Gly, Met₁₈₀ is replaced with Cys, Arg₁₈₁ is replaced with Leu or Ser, Pro₁₈₂ is replaced with Leu or Ser, Ser₉₈ is replaced with Asp, Ser₂₅₅ is replaced with Ala or Leu, Leu₁₉₈ is replaced with Lys, which mutant EPSPS protein has increased resistance or tolerance to a herbicide, which herbicide is a member of the phosphonomethylglycine family.

15

20

25

30

35

ABSTRACT

The present invention relates to the production of a non-transgenic plant resistant or tolerant to a herbicide of the phosphonomethylglycine family, *e.g.*, glyphosate. The present invention also relates to the use of a recombinogenic oligonucleobase to make a desired mutation in the chromosomal or episomal sequences of a plant in the gene encoding for 5-enol pyruvylshikimate-3-phosphate synthase (EPSPS). The mutated protein, which substantially maintains the catalytic activity of the wild-type protein, allows for increased resistance or tolerance of the plant to a herbicide of the phosphonomethylglycine family, and allows for the substantially normal growth or development of the plant, its organs, tissues or cells as compared to the wild-type plant irrespective of the presence or absence of the herbicide. The present invention also relates to a non-transgenic plant cell in which the EPSPS gene has been mutated, a non-transgenic plant regenerated therefrom, as well as a plant resulting from a cross using a regenerated non-transgenic plant having a mutated EPSPS gene.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470
471
472
473
474
475
476
477
478
479
480
481
482
483
484
485
486
487
488
489
490
491
492
493
494
495
496
497
498
499
500
501
502
503
504
505
506
507
508
509
510
511
512
513
514
515
516
517
518
519
520
521
522
523
524
525
526
527
528
529
530
531
532
533
534
535
536
537
538
539
540
541
542
543
544
545
546
547
548
549
550
551
552
553
554
555
556
557
558
559
560
561
562
563
564
565
566
567
568
569
570
571
572
573
574
575
576
577
578
579
580
581
582
583
584
585
586
587
588
589
590
591
592
593
594
595
596
597
598
599
600
601
602
603
604
605
606
607
608
609
610
611
612
613
614
615
616
617
618
619
620
621
622
623
624
625
626
627
628
629
630
631
632
633
634
635
636
637
638
639
640
641
642
643
644
645
646
647
648
649
650
651
652
653
654
655
656
657
658
659
660
661
662
663
664
665
666
667
668
669
670
671
672
673
674
675
676
677
678
679
680
681
682
683
684
685
686
687
688
689
690
691
692
693
694
695
696
697
698
699
700
701
702
703
704
705
706
707
708
709
710
711
712
713
714
715
716
717
718
719
720
721
722
723
724
725
726
727
728
729
730
731
732
733
734
735
736
737
738
739
740
741
742
743
744
745
746
747
748
749
750
751
752
753
754
755
756
757
758
759
760
761
762
763
764
765
766
767
768
769
770
771
772
773
774
775
776
777
778
779
780
781
782
783
784
785
786
787
788
789
790
791
792
793
794
795
796
797
798
799
800
801
802
803
804
805
806
807
808
809
810
811
812
813
814
815
816
817
818
819
820
821
822
823
824
825
826
827
828
829
830
831
832
833
834
835
836
837
838
839
840
841
842
843
844
845
846
847
848
849
850
851
852
853
854
855
856
857
858
859
860
861
862
863
864
865
866
867
868
869
870
871
872
873
874
875
876
877
878
879
880
881
882
883
884
885
886
887
888
889
890
891
892
893
894
895
896
897
898
899
900
901
902
903
904
905
906
907
908
909
910
911
912
913
914
915
916
917
918
919
920
921
922
923
924
925
926
927
928
929
930
931
932
933
934
935
936
937
938
939
940
941
942
943
944
945
946
947
948
949
950
951
952
953
954
955
956
957
958
959
960
961
962
963
964
965
966
967
968
969
970
971
972
973
974
975
976
977
978
979
980
981
982
983
984
985
986
987
988
989
990
991
992
993
994
995
996
997
998
999
1000
1001
1002
1003
1004
1005
1006
1007
1008
1009
1010
1011
1012
1013
1014
1015
1016
1017
1018
1019
1020
1021
1022
1023
1024
1025
1026
1027
1028
1029
1030
1031
1032
1033
1034
1035
1036
1037
1038
1039
1040
1041
1042
1043
1044
1045
1046
1047
1048
1049
1050
1051
1052
1053
1054
1055
1056
1057
1058
1059
1060
1061
1062
1063
1064
1065
1066
1067
1068
1069
1070
1071
1072
1073
1074
1075
1076
1077
1078
1079
1080
1081
1082
1083
1084
1085
1086
1087
1088
1089
1090
1091
1092
1093
1094
1095
1096
1097
1098
1099
1100
1101
1102
1103
1104
1105
1106
1107
1108
1109
1110
1111
1112
1113
1114
1115
1116
1117
1118
1119
1120
1121
1122
1123
1124
1125
1126
1127
1128
1129
1130
1131
1132
1133
1134
1135
1136
1137
1138
1139
1140
1141
1142
1143
1144
1145
1146
1147
1148
1149
1150
1151
1152
1153
1154
1155
1156
1157
1158
1159
1160
1161
1162
1163
1164
1165
1166
1167
1168
1169
1170
1171
1172
1173
1174
1175
1176
1177
1178
1179
1180
1181
1182
1183
1184
1185
1186
1187
1188
1189
1190
1191
1192
1193
1194
1195
1196
1197
1198
1199
1200
1201
1202
1203
1204
1205
1206
1207
1208
1209
1210
1211
1212
1213
1214
1215
1216
1217
1218
1219
1220
1221
1222
1223
1224
1225
1226
1227
1228
1229
1230
1231
1232
1233
1234
1235
1236
1237
1238
1239
1240
1241
1242
1243
1244
1245
1246
1247
1248
1249
1250
1251
1252
1253
1254
1255
1256
1257
1258
1259
1260
1261
1262
1263
1264
1265
1266
1267
1268
1269
1270
1271
1272
1273
1274
1275
1276
1277
1278
1279
1280
1281
1282
1283
1284
1285
1286
1287
1288
1289
1290
1291
1292
1293
1294
1295
1296
1297
1298
1299
1300
1301
1302
1303
1304
1305
1306
1307
1308
1309
1310
1311
1312
1313
1314
1315
1316
1317
1318
1319
1320
1321
1322
1323
1324
1325
1326
1327
1328
1329
1330
1331
1332
1333
1334
1335
1336
1337
1338
1339
1340
1341
1342
1343
1344
1345
1346
1347
1348
1349
1350
1351
1352
1353
1354
1355
1356
1357
1358
1359
1360
1361
1362
1363
1364
1365
1366
1367
1368
1369
1370
1371
1372
1373
1374
1375
1376
1377
1378
1379
1380
1381
1382
1383
1384
1385
1386
1387
1388
1389
1390
1391
1392
1393
1394
1395
1396
1397
1398
1399
1400
1401
1402
1403
1404
1405
1406
1407
1408
1409
1410
1411
1412
1413
1414
1415
1416
1417
1418
1419
1420
1421
1422
1423
1424
1425
1426
1427
1428
1429
1430
1431
1432
1433
1434
1435
1436
1437
1438
1439
1440
1441
1442
1443
1444
1445
1446
1447
1448
1449
1450
1451
1452
1453
1454
1455
1456
1457
1458
1459
1460
1461
1462
1463
1464
1465
1466
1467
1468
1469
1470
1471
1472
1473
1474
1475
1476
1477
1478
1479
1480
1481
1482
1483
1484
1485
1486
1487
1488
1489
1490
1491
1492
1493
1494
1495
1496
1497
1498
1499
1500
1501
1502
1503
1504
1505
1506
1507
1508
1509
1510
1511
1512
1513
1514
1515
1516
1517
1518
1519
1520
1521
1522
1523
1524
1525
1526
1527
1528
1529
1530
1531
1532
1533
1534
1535
1536
1537
1538
1539
1540
1541
1542
1543
1544
1545
1546
1547
1548
1549
1550
1551
1552
1553
1554
1555
1556
1557
1558
1559
1560
1561
1562
1563
1564
1565
1566
1567
1568
1569
1570
1571
1572
1573
1574
1575
1576
1577
1578
1579
1580
1581
1582
1583
1584
1585
1586
1587
1588
1589
1590
1591
1592
1593
1594
1595
1596
1597
1598
1599
1600
1601
1602
1603
1604
1605
1606
1607
1608
1609
1610
1611
1612
1613
1614
1615
1616
1617
1618
1619
1620
1621
1622
1623
1624
1625
1626
1627
1628
1629
1630
1631
1632
1633
1634
1635
1636
1637
1638
1639
1640
1641
1642
1643
1644
1645
1646
1647
1648
1649
1650
1651
1652
1653
1654
1655
1656
1657
1658
1659
1660
1661
1662
1663
1664
1665
1666
1667
1668
1669
1670
1671
1672
1673
1674
1675
1676
1677
1678
1679
1680
1681
1682
1683
1684
1685
1686
1687
1688
1689
1690
1691
1692
1693
1694
1695
1696
1697
1698
1699
1700
1701
1702
1703
1704
1705
1706
1707
1708
1709
1710
1711
1712
1713
1714
1715
1716
1717
1718
1719
1720
1721
1722
1723
1724
1725
1726
1727
1728
1729
1730
1731
1732
1733
1734
1735
1736
1737
1738
1739
1740
1741
1742
1743
1744
1745
1746
1747
1748
1749
1750
1751
1752
1753
1754
1755
1756
1757
1758
1759
1760
1761
1762
1763
1764
1765
1766
1767
1768
1769
1770
1771
1772
1773
1774
1775
1776
1777
1778
1779
1780
1781
1782
1783
1784
1785
1786
1787
1788
1789
1790
1791
1792
1793
1794
1795
1796
1797
1798
1799
1800
1801
1802
1803
1804
1805
1806
1807
1808
1809
1810
1811
1812
1813
1814
1815
1816
1817
1818
1819
1820
1821
1822
1823
1824
1825
1826
1827
1828
1829
1830
1831
1832
1833
1834
1835
1836
1837
1838
1839
1840
1841
1842
1843
1844
1845
1846
1847
1848
1849
1850
1851
1852
1853
1854
1855
1856
1857
1858
1859
1860
1861
1862
1863
1864
1865
1866
1867
1868
1869
1870
1871
1872
1873
1874
1875
1876
1877
1878
1879
1880
1881
1882
1883
1884
1885
1886
1887
1888
1889
1890
1891
1892
1893
1894
1895
1896
1897
1898
1899
1900
1901
1902
1903
1904
1905
1906
1907
1908
1909
1910
1911
1912
1913
1914
1915
1916
1917
1918
1919
1920
1921
1922
1923
1924
1925
1926
1927
1928
1929
1930
1931
1932
1933
1934
1935
1936
1937
1938
1939
1940
1941
1942
1943
1944
1945
1946
1947
1948
1949
1950
1951
1952
1953
1954
1955
1956
1957
1958
1959
1960
1961
1962
1963
1964
1965
1966
1967
1968
1969
1970
1971
1972
1973
1974
1975
1976
1977
1978
1979
1980
1981
1982
1983
1984
1985
1986
1987
1988
1989
1990
1991
1992
1993
1994
1995
1996
1997
1998
1999
2000
2001
2002
2003
2004
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
2032
2033
2034
2035
2036
2037
2038
2039
2040
2041
2042
2043
2044
2045
2046
2047
2048
2049
2050
2051
2052
2053
2054
2055
2056
2057
2058
2059
2060
2061
2062
2063
2064
2065
2066
2067
2068
2069
2070
2071
2072
2073
2074
2075
2076
2077
2078
2079
2080
2081
2082
2083
2084
2085
2086
2087
2088
2089
2090
2091
2092
2093
2094
2095
2096
2097
2098
2099
2100
2101
2102
2103
2104
2105
2106
2107
2108
2109
2110
2111
2112
2113
2114
2115
2116
2117
2118
2119
2120
2121
2122
2123
2124
2125
2126
2127
2128
2129
2130
2131
2132
2133
2134
2135
2136
2137
2138
2139
2140
2141
2142
2143
2144
2145
2146
2147
2148
2149
2150
2151
2152
2153
2154
2155
2156
2157
2158
2159
2160
2161
2162
2163
2164
2165
2166
2167
2168
2169
2170
2171
2172
2173
2174
2175
2176
2177
2178
2179
2180
2181
2182
2183
2184
2185
2186
2187
2188
2189
2190
2191
2192
2193
2194

DNA sequence:

cccttcagtcctctttagtagaaaccccatatctcttcttagggcccaattgaaaaccacattttcttctacctaaccgac
caagcctctgcacatgttgagctggaacccaacaaactaacacgtgtcactcgcagtggttatgataaaatgctcatccat
accagagtcataagagttttgggtgggtgaaagatttgacggatgccttctcttcatttcttccacaaactcctccaaaccc
aacaaaaatgttataattagcaaacgcccgaagtgtaaacgaaagttataaaatttcattctctgtgatttactgtaattg
gaggaagatcaaaatttccaatccccattctctcgatgcttcaattgaagttcttcg

[transit peptide start]

ATGGCGCAAGTTAGCAGAATCTGCAATGGTGTGCAGAACCCATCTCTTATCTCCAATCTCTCGAAATCCAGTCAACGCCAA
ATCTCCCTTATCGGTTTCTCTGAAGACGCAGCAGCATCCACGAGCTTATCCGATTTCTGCTGCTCGGGGATTGAAGAA
GTGGGATGACGTTAATGGCTCTGAGCTTCGCTCTTCTTAAGGTATGCTCTCTGTTTCCACGCGCGAG

[mature peptide starts]

AAAGCGTCGGAGATTGTACTTCAACCATTAGAGAAATCTCCGGTCTTATTAAGCTTCTCGGTCTCAAGTCTCTATCAAA
TCGGATCTCGTCTTCTCGTGTCTGCTGAGGTATATATCACTTCGTTCTCTGTAACCTGAACTTAGATTAT
AAAGATTGATACCTTTACCATTCTGCTGTGGTTTATAGGGAACAACTGTAGTGGACAACTTGTGAATAGCGATGACATC
AATTACATGCTGTGATGCGTTGAAGAGATTGGGACTTAATGTGGAACTGACAGTGAATAATCTGTGTGTGAAAG
ATGTGGCGGGATTTCCAGCTTCCATAGATTCAAGAGGTGATTCGAACCTTACCTCGTAATCAGGAACAGCAATGC
GTCCACTTACCCTCGGGTCACTGCTGCAGGTGGAAACGCAAGGTAGATTGAAGAGTGTGATGCTTCTGGTATTTGATG
TTTAAGGAATGGAGCTTTGTGTTATGCTTTATGATCATTATTCCAGTTATGTGCTGTGAGGGTGCCTCGTATGAGAG
AAAGACCTATAGAGCTTTGTGTTATGCTTTATGATCATTATTCCAGTTATGTGCTGTGAGGGTGCCTCGTATGAGAG
CCTGTTCTGTGTCAAGCTAATAGTGGGCTTCCCGGTGGAAAGGTAGATTGCTTGAATAGGATGTAATATGTAATCTCG
TTCTCTTACTCTATGAACACTTGCAGAAATGTGTGTTTCATCATAGCCTTAGCTTGACAAAGATTTCAAGTTTTATCTACTC
TCACCGGATGGATCCTAAATAGAAATCGGATTGGTGATTGGTTTTCTGTTCTCGATTACCGTTTTCTGTTGATGATTCT
TGATTAAACAAATAGGAGACATGTTATGATTTCAGAGTGAAGCTTTCTGGATCAATTAGTAGTCAGTACTTGACTGCTCT
GCTCATGCTCTGCTCCCTTAGCTTTGAGAGACGTCGAGATTGAGATTGTGATAAATTAATTTCTGTTCCATATGTTGAAA
TGACATGTGAAGTTGATGGAACGTTTCCGGGTTAGTGTGAGCATAGTATAGCTGGGATCGTTTTCTTGTCAAGGGCGG
CAAAAAATACAAGTAGGAGTTATTCTTTCTTCTCTTTCTGAAATCACATCCCTTAGCTTGACAAATATAAGTACTAAAAG
TGAAATGATTCAGGCTCTCGGGTAATGCGTATGTAGAAGGTGATGCTCTTATGTGACGTTATGCTTCTGCTGCTGCTGCTG
TTACCGGTGAACTGTACAGTGAAGGTTGTGAACTACCACTGCTTACAGGTATATTTGTACAACTGAACTATTCGCAAGATTC
GCTGTTAAGTTTATAGTGAATTTCTGCTAGGTCAAAAGTTTCACTCTTTGACAAAGTTGATATAACAACTATTCGCAAGATTC
TAAGCTCAATTTTTGTGATGAATCTCTAGGGAGATGTAATAATTCGCGAGGTCCTTGAGAAATGGGATGTAAGGTGTC
TGGACAGAGAACAGTGTGACTGTGACAGGACCACTAGAGATGCTTTGGAATGAGACACTTGGGGGCTATTGATGTCAA
CATGAGCAAAATGCTGATGTAGCCATGACCTTCCCTCGTGTGCTCTTTGCTGACGCTTCAACCAACCATTAGAGATG
GTAAGTAAAAAGCTCTCTCTTATAAATTAAGGTTTCTCAATATTATGATGACCTTAATCTGTTGGTTAATATAGTGGCT
AGCTGTGAGAGTAAGGAGACAGAAAGGATGATTGCCATTTGCACAGAGCTTAGAAAGTAAAGAGATTCTTATCTCTCTCT
TTCTGCTCTTGACAGTGTCTTCTAAGTAATTAGCTCATAAATTTGTGTTTGTGTTGCTACAGTGGGAGCTACAGTGG
AGAAGGTTTCAAGTTATTGTGTGATAACTCGCCCAAAAGGTGAAACGCGCAGAGATTGATACATATGATGATCATAGAA
TGCGCAATGGACTTCTCTTCTGAGCTTGTGCTGATGTTTCCAATCACCATCAACGACTCTGGTTTGCACGAGGAAACCTTC
CCGCACTACTTCCAAGTACTTGAAGAAATCACAAAGCACTAaacaataaactcgtttttctctcgatccagagtt

FIG. 1A

Protein sequence:

MAQVSRI^CNGVQNP^SLI^NLS^KSSQ^RKS^PLSV^SLK^TQ^QHPRAY^PISS^SWGL^KKS^QNTL^IGSEL^RPLK^VMS^SSV^STAE
KASEI^VLQ^PI^REIS^GLI^KLP^GSK^SLS^NRILL^LLAAL^SEG^TTV^DNL^NSD^DIN^YMLD^ALK^RLGL^NVET^DSEN^NRAV^V
EGCG^GI^FPAS^IDS^KSDI^ELY^LGN^AG^TAM^RPL^TAAV^TAAG^NAS^YVL^DGV^FMR^RER^PIG^DLV^VGL^KQL^GAD^VECT^LG
TNC^PPF^VRVN^ANG^LPG^GK^VKL^SGS^ISS^QYL^TAL^IMS^APL^ALGD^VEI^EI^VDK^LI^SVP^YY^EMT^LKI^MER^FGV^SVEH^SD
SW^DRF^FV^KGG^QQ^YK^SPG^NAY^VEG^DASS^AC^YFLA^GAA^ITG^ETV^TVEG^CGT^TSL^QQ^DV^KFA^EVL^EK^MGC^KV^SWTEN^SV
TV^TGP^PRD^AFG^MRHL^RAI^DVN^MN^KMP^DVAM^TLAV^ALFAD^GPT^TIR^DVAS^RW^VKETER^MIA^ICTEL^RKLG^ATVEE^G
SD^YCVIT^PPK^VK^TAE^IDT^YDD^HRMAM^AFS^LAAC^ADV^PIT^IND^SGC^TRK^TFP^DY^FQV^LERIT^KH

FIG. 1B

Arabidopsis thaliana wild type sequence:

Position	173	174	175	176	177	178	179	180	181	182	183
	L	G	N	A	G	T	A	M	R	P	L
	CTC	GGT	AAT	GCA	GGA	ACA	GCA	ATG	CGT	CCA	CTT

Arabidopsis thaliana mutant sequences:

Name

A ₁₇₇	CTC	GGT	AAT	GCA	GCA	ACA	GCA	ATG	CGT	CCA	CTT
	L	G	N	A	A	T	A	M	R	P	L
I ₁₇₈	CTC	GGT	AAT	GCA	GGA	ATA	GCA	ATG	CGT	CCA	CTT
	L	G	N	A	G	I	A	M	R	P	L
A ₁₇₇ I ₁₇₈	CTC	GGT	AAT	GCA	GCA	ATA	GCA	ATG	CGT	CCA	CTT
	L	G	N	A	A	I	A	M	R	P	L
I ₁₇₈ S ₁₈₂	CTC	GGT	AAT	GCA	GGA	ATA	GCA	ATG	CGT	TCA	CTT
	L	G	N	A	G	I	A	M	R	S	L
A ₁₇₇ S ₁₈₂	CTC	GGT	AAT	GCA	GCA	ACA	GCA	ATG	CGT	TCA	CTT
	L	G	N	A	A	T	A	M	R	S	L
A ₁₇₇ I ₁₇₈ S ₁₈₂	CTC	GGT	AAT	GCA	GCA	ATA	GCA	ATG	CGT	TCA	CTT
	L	G	N	A	A	I	A	M	R	S	L
V ₁₇₈ S ₁₈₂	CTC	GGT	AAT	GCA	GGA	GTA	GCA	ATG	CGT	TCA	CTT
	L	G	N	A	G	V	A	M	R	S	L
L ₁₇₈ S ₁₈₂	CTC	GGT	AAT	GCA	GGA	TTA	GCA	ATG	CGT	TCA	CTT
	L	G	N	A	G	L	A	M	R	S	L
A ₁₇₇ V ₁₇₈	CTC	GGT	AAT	GCA	GCA	GTA	GCA	ATG	CGT	CCA	CTT
	L	G	N	A	A	V	A	M	R	P	L
A ₁₇₇ L ₁₇₈	CTC	GGT	AAT	GCA	GCA	TTA	GCA	ATG	CGT	CCA	CTT
	L	G	N	A	A	L	A	M	R	P	L

FIG. 2





FIG. 3A

[illegible]

FIG. 3B

FIG. 3C



	10	20	30	40	50	60	70	80	90	100	
1	MAQUSRLCMGQNP	SLINSLNKSORSKSLVSLKQHP	PRAYTSSMGLKSKTSGLSELR	-----	PLKVNSSVSVA	EKASELVI	OPTRELSGLIKL	PGSKLSLN	atepaps. PRO		
1	MAQUSRLCMGQNP	CVTINSLNKSORSKSLVSLKTHQ	-----	PRASSMGLKSKTSLANGSVTR	-----	PVIVATVSVTS	SEASELVI	OPTRELSGLIKL	PGSKLSLN	bnepaps. PRO	
1	MAQINNAQSGITL	NFZNSGNHKQVFKSGSFLVSGKK	-----	LKNSA	-----	NEMVLKUDST	FHOKFCSFI	SASVATQK	PSEVITLOPTKISGTVL	PGSKLSLN	petaraoa. PRO
1	AG								ASEIVLOPTKISGTVL	PGSKLSLN	znepaps. PRO
104	RILLALALSSGTVV	VDNLLNSDDIN	FDALKRLGAW	ETDSERNRAV	VECCGIGIF	SPASIDS	KSDELE	VLNAGTANMR	PLTAANTV	AAAGNSASTVLDGVP	PIHERRPIDLV
100	RILLALALSSGTVV	VDNLLNSDDIN	YMLDALKRLGAW	ETDSERNRAV	VECCGIGIF	SPASIDS	KSDELE	VLNAGTANMR	PLTAANTV	AAAGNSASTVLDGVP	PIHERRPIDLV
100	RILLALALSSGTVV	VDNLLNSDDIN	YMLDALKRLGAW	ETDSERNRAV	VECCGIGIF	SPASIDS	KSDELE	VLNAGTANMR	PLTAANTV	AAAGNSASTVLDGVP	PIHERRPIDLV
29	RILLALALSSGTVV	VDNLLNSDDIN	YMLDALKRLGAW	ETDSERNRAV	VECCGIGIF	SPASIDS	KSDELE	VLNAGTANMR	PLTAANTV	AAAGNSASTVLDGVP	PIHERRPIDLV
214	VLKXQJGADHVECTL	GTACQPPVRVANGGL	PGSKVYL	SGSTSSQVIT	LALNSAPAL	ADVELEIV	DLKLSV	PVVENTUKL	MEHGV	SVHSSSNORPTV	KGGOQVYKSPKNA
210	VLKXQJGADHVECTL	GTACQPPVRVANGGL	PGSKVYL	SGSTSSQVIT	LALNSAPAL	ADVELEIV	DLKLSV	PVVENTUKL	MEHGV	SVHSSSNORPTV	KGGOQVYKSPKNA
210	VLKXQJGADHVECTL	GTACQPPVRVANGGL	PGSKVYL	SGSTSSQVIT	LALNSAPAL	ADVELEIV	DLKLSV	PVVENTUKL	MEHGV	SVHSSSNORPTV	KGGOQVYKSPKNA
138	VLKXQJGADHVECTL	GTACQPPVRVANGGL	PGSKVYL	SGSTSSQVIT	LALNSAPAL	ADVELEIV	DLKLSV	PVVENTUKL	MEHGV	SVHSSSNORPTV	KGGOQVYKSPKNA
324	YVEGBASSACVFL	AGAAITGENTV	VECCGTTSH	QDVKRPAE	LEKRGKSV	TVTWSV	TVU	PROJAGMREH	LAIDUN	NKHPDVA	NTLAAVAFADGPTPIH
320	YVEGBASSACVFL	AGAAITGENTV	VECCGTTSH	QDVKRPAE	LEKRGKSV	TVTWSV	TVU	PROJAGMREH	LAIDUN	NKHPDVA	NTLAAVAFADGPTPIH
320	YVEGBASSACVFL	AGAAITGENTV	VECCGTTSH	QDVKRPAE	LEKRGKSV	TVTWSV	TVU	PROJAGMREH	LAIDUN	NKHPDVA	NTLAAVAFADGPTPIH
248	YVEGBASSACVFL	AGAAITGENTV	VECCGTTSH	QDVKRPAE	LEKRGKSV	TVTWSV	TVU	PROJAGMREH	LAIDUN	NKHPDVA	NTLAAVAFADGPTPIH
434	KETERMIAICTEL	RLKLGATVEES	SYCVIT	TPPKVKTAC	ITDVTDO	HRMANAF	SLAACADVP	TTIND	SSCTKRT	PPDYQV	LKRTIKH
430	KETERMIAICTEL	RLKLGATVEES	SYCVIT	TPPKVKTAC	ITDVTDO	HRMANAF	SLAACADVP	TTIND	SSCTKRT	PPDYQV	LKRTIKH
430	KETERMIAICTEL	RLKLGATVEES	SYCVIT	TPPKVKTAC	ITDVTDO	HRMANAF	SLAACADVP	TTIND	SSCTKRT	PPDYQV	LKRTIKH
158	KETERMIAICTEL	RLKLGATVEES	SYCVIT	TPPKVKTAC	ITDVTDO	HRMANAF	SLAACADVP	TTIND	SSCTKRT	PPDYQV	LKRTIKH

FIG. 4

Oligo Name Oligo Sequence (5'→3')

ATEPS-A₁₇₇

CGTTTCCACCTGCAGCAGTGACCGCAGCGGTAAGTGGACGCATTGCTGTTGCTGCATTACCGAG

ATEPS-AI

CGTTTCCACCTGCAGCAGTGACCGCAGCGGTAAGTGGACGCATTGCTATTGCTGCATTACCGAG

ATEPS-IS

CGTTTCCACCTGCAGCAGTGACCGCAGCGGTAAGTGGACGCATTGCTATTGCTGCATTACCGAG

ATEPS-AS

CGTTTCCACCTGCAGCAGTGACCGCAGCGGTAAGTGGACGCATTGCTGTTGCTGCATTACCGAG

ATEPS-AIS

CGTTTCCACCTGCAGCAGTGACCGCAGCGGTAAGTGGACGCATTGCTATTGCTGCATTACCGAG

ATEPS-I₁₇₇

CGTTTCCACCTGCAGCAGTGACCGCAGCGGTAAGTGGACGCATTGCTGTTATTGCATTACCGAG

ATEPS-VS

CGTTTCCACCTGCAGCAGTGACCGCAGCGGTAAGTGGACGCATTGCTACTGCTGCATTACCGAG

ATEPS-LS

CGTTTCCACCTGCAGCAGTGACCGCAGCGGTAAGTGGACGCATTGCTAACTGCTGCATTACCGAG

ATEPS-AV

CGTTTCCACCTGCAGCAGTGACCGCAGCGGTAAGTGGACGCATTGCTACTGCTGCATTACCGAG

ATEPS-AL

CGTTTCCACCTGCAGCAGTGACCGCAGCGGTAAGTGGACGCATTGCTAATGCTGCATTACCGAG

FIG. 5




FIG. 6

66
45

66 →
45 →




FIG. 7

**DECLARATION
AND POWER OF ATTORNEY**

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below at 201 et seq. underneath my name.

I believe I am the original, first and sole inventor if only one name is listed at 201 below, or an original, first and joint inventor if plural names are listed at 201 et seq. below, of the subject matter which is claimed and for which a patent is sought on the invention entitled

NON-TRANSGENIC HERBICIDE RESISTANT PLANTS

and for which a patent application:

- ☒ is attached hereto and includes amendment(s) filed on (if applicable)
☐ was filed in the United States on as Application No. (for declaration not accompanying application)
 with amendment(s) filed on (if applicable)
☐ was filed as PCT international Application No. on and was amended under PCT Article 19 on (if applicable)

I hereby state that I have reviewed and understand the contents of the above identified application, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information known to me to be material to patentability as defined in Title 37, Code of Federal Regulations, §1.56.

I hereby claim foreign priority benefits under Title 35, United States Code, §119(a)-(d) of any foreign application(s) for patent or inventor's certificate listed below and have also identified below any foreign application for patent or inventor's certificate having a filing date before that of the application on which priority is claimed:

EARLIEST FOREIGN APPLICATION(S), IF ANY, FILED PRIOR TO THE FILING DATE OF THE APPLICATION			
APPLICATION NUMBER	COUNTRY	DATE OF FILING (day, month, year)	PRIORITY CLAIMED
			YES <input type="checkbox"/> NO <input type="checkbox"/>
			YES <input type="checkbox"/> NO <input type="checkbox"/>

I hereby claim the benefit under Title 35, United States Code, §119(e) of any United States provisional application(s) listed below.

APPLICATION NUMBER	FILING DATE
60/158,027	October 7, 1999
60/173,564	December 30, 1999

I hereby claim the benefit under Title 35, United States Code, §120 of any United States application(s) listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner provided by the first paragraph of Title 35, United States Code §112, I acknowledge the duty to disclose information which is material to patentability as defined in Title 37, Code of Federal Regulations, §1.56 which became available between the filing date of the prior application and the national or PCT international filing date of this application:

APPLICATION SERIAL NO.	FILING DATE	STATUS		
		PATENTED	PENDING	ABANDONED

POWER OF ATTORNEY. As a named inventor, I hereby appoint S. Leslie Miskrock (Reg. No. 18872), Harry C. Jones, III (Reg. No. 20280), Bert A. Terzian (Reg. No. 20060), David Weild, III (Reg. No. 21094), Jonathan A. Marshall (Reg. No. 24614), Barry D. Rein (Reg. No. 22411), Stanton T. Lawrence, III (Reg. No. 25736), Charles E. McKenney (Reg. No. 22795), Philip T. Shannon (Reg. No. 24278), Francis E. Morris (Reg. No. 24615), Charles E. Miller (Reg. No. 24576), Gidon D. Stern (Reg. No. 27469), John J. Lauter, Jr. (Reg. No. 27814), Brian M. Poissant (Reg. No. 28402), Brian D. Coggio (Reg. No. 27624), Rory J. Radding (Reg. No. 28749), Stephen J. Harbulak (Reg. No. 29166), Donald J. Goodell (Reg. No. 19766), James N. Paik (Reg. No. 25510), Thomas E. Freibel (Reg. No. 29258), Laura A. Coruzzi (Reg. No. 30742), Jennifer Gordon (Reg. No. 30753), Allan A. Fanucci (Reg. No. 30256), Geraldine F. Baldwin (Reg. No. 31232), Victor N. Balancia (Reg. No. 31231), Samuel B. Abrams (Reg. No. 30605), Steven I. Wallach (Reg. No. 35402), Marcia H. Sundeen (Reg. No. 30893), Paul J. Zegger (Reg. No. 33821), Edmond R. Bannon (Reg. No. 32110), Bruce J. Barker (Reg. No. 33291), Adriane M. Antler (Reg. No. 32605), Thomas G. Rowan (Reg. No. 34419), James G. Markey (Reg. No. 31636), Thomas D. Kohler (Reg. No. 32797), Scott D. Simpson (Reg. No. 33607), Gary S. Williams (Reg. No. 31066), William S. Galliani (Reg. No. 33855), Ann L. Gniolfi (Reg. No. 31956), Todd A. Wagner (Reg. No. 35399), Scott B. Famulant (Reg. No. 35314), Kelly D. Talcott (Reg. No. 39582), Francis D. Cerrito (Reg. No. 38100), Anthony M. Insigna (Reg. No. 35203), Brian M. Rothery (Reg. No. 35340), Brian D. Siff (Reg. No. 35679), and Alan Tenenbaum (Reg. No. 34939), all of Pennie & Edmonds LLP, whose addresses are 1155 Avenue of the Americas, New York, New York 10036, 1667 K Street N.W., Washington, DC 20006 and 3300 Hillview Avenue, Palo Alto, CA 94304, and each of them, my attorneys, to prosecute this application, and to transact all business in the Patent and Trademark Office connected therewith.

SEND CORRESPONDENCE TO:		PENNIE & EDMONDS LLP 1155 Avenue of the Americas New York, N.Y. 10036-2711		DIRECT TELEPHONE CALLS TO: PENNIE & EDMONDS LLP DOCKETING (212) 790-2803	
201	FULL NAME OF INVENTOR	LAST NAME BEETHAM	FIRST NAME PETER	MIDDLE NAME R.	
	RESIDENCE & CITIZENSHIP	CITY CARLSBAD	STATE OR FOREIGN COUNTRY CALIFORNIA	COUNTRY OF CITIZENSHIP AUSTRALIA	
	POST OFFICE ADDRESS	STREET 7128 TANAGER DRIVE	CITY CARLSBAD	STATE OR COUNTRY CALIFORNIA	ZIP CODE 92009
202	FULL NAME OF INVENTOR	LAST NAME AVISSAR	FIRST NAME PATRICIA	MIDDLE NAME L.	
	RESIDENCE & CITIZENSHIP	CITY EAST BRUNSWICK	STATE OR FOREIGN COUNTRY NEW JERSEY	COUNTRY OF CITIZENSHIP UNITED STATES	
	POST OFFICE ADDRESS	STREET 32 REVOCK ROAD	CITY EAST BRUNSWICK	STATE OR COUNTRY NEW JERSEY	ZIP CODE 08816
203	FULL NAME OF INVENTOR	LAST NAME WALKER	FIRST NAME KEITH	MIDDLE NAME A.	
	RESIDENCE & CITIZENSHIP	CITY SAN DIEGO	STATE OR FOREIGN COUNTRY CALIFORNIA	COUNTRY OF CITIZENSHIP UNITED STATES	
	POST OFFICE ADDRESS	STREET 13315 ROXTON CIRCLE	CITY SAN DIEGO	STATE OR COUNTRY CALIFORNIA	ZIP CODE 92130
204	FULL NAME OF INVENTOR	LAST NAME METZ	FIRST NAME RICHARD	MIDDLE NAME A.	
	RESIDENCE & CITIZENSHIP	CITY LAWRENCEVILLE	STATE OR FOREIGN COUNTRY NEW JERSEY	COUNTRY OF CITIZENSHIP UNITED STATES	
	POST OFFICE ADDRESS	STREET 37 WINTHROP ROAD	CITY LAWRENCEVILLE	STATE OR COUNTRY NEW JERSEY	ZIP CODE 08648

I HEREBY DECLARE THAT ALL STATEMENTS MADE HEREIN OF MY OWN KNOWLEDGE ARE TRUE AND THAT ALL STATEMENTS MADE ON INFORMATION AND BELIEF ARE BELIEVED TO BE TRUE; AND FURTHER THAT THESE STATEMENTS WERE MADE WITH THE KNOWLEDGE THAT WILLFUL FALSE STATEMENTS AND THE LIKE SO MADE ARE PUNISHABLE BY FINE OR IMPRISONMENT, OR BOTH, UNDER SECTION 1001 OF TITLE 18 OF THE UNITED STATES CODE AND THAT SUCH WILLFUL FALSE STATEMENTS MAY JEOPARDIZE THE VALIDITY OF THE APPLICATION OR ANY PATENT ISSUING THEREON.

SIGNATURE OF INVENTOR 201	SIGNATURE OF INVENTOR 202	SIGNATURE OF INVENTOR 203
PETER R. BEETHAM	PATRICIA L. AVISSAR	KEITH A. WALKER
DATE:	DATE:	DATE:
SIGNATURE OF INVENTOR 204		
RICHARD A. METZ		
DATE:		

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Beetham et al.

Application No.: To be assigned

Group Art Unit: To be assigned

Filed: On even date herewith

Examiner: To be assigned

For: NON-TRANSGENIC HERBICIDE
RESISTANT PLANTS

Attorney Docket No.: 7991-086

TRANSMITTAL OF SEQUENCE LISTING UNDER 37 C.F.R. § 1.821

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

In accordance with 37 C.F.R. § 1.821, Applicants, in connection with the above-identified patent application, submit herewith a Sequence Listing in paper and computer readable form pursuant to 37 C.F.R. §§ 1.821(c) and (e).

I hereby state that the content of the paper and computer readable copies of the Sequence Listing, submitted in accordance with 37 C.F.R. §§ 1.821(c) and (e), respectively, are the same.

Respectfully submitted,

Date: October 10, 2000

by Helen R. Rumm
Thomas E. Friebe

Thomas E. Friebe 29,258
(Reg.No.)

PENNIE & EDMONDS LLP
1155 Avenue of the Americas
New York, New York 10036-2711
(212) 790-9090

Enclosures

SEQUENCE LISTING

<110> Beetham, P.
Avisar, P.
Walker, K.
Metz, R.

<120> NON-TRANSGENIC HERBICIDE RESISTANT PLANTS

<130> 7991-086

<150> 60/158,027

<151> 1999-10-07

<150> 60/173,564

<151> 1999-12-30

<160> 44

<170> FastSEQ for Windows Version 3.0

<210> 1

<211> 2763

<212> DNA

<213> Arabidopsis thaliana

<400> 1

cccttcatgt	ctttttaga	aacccatta	tctttcttag	ggcccaattg	aaaaccaca	60
ttttcttcca	cctaaccac	caaagccttg	cacatgttga	cgtgaacacc	aaactaacac	120
gtgtcatact	gcagatggtt	atgataaatg	ctcataccat	accagagatc	tagagtcttt	180
ggttggtaga	agatttgacg	gatgccttct	tctcatttct	caccaactcc	ctccaaaccc	240
aacaaaaagt	ttatattagc	aaagccgcga	aagtgtaaac	gaaagtttat	aaatttctat	300
tctgtgatct	tacgtaattg	gaggaagatc	aaaattttca	atccccattc	ttcgaattgt	360
tcaattgaag	tttctccgat	ggcgcaagtt	agcagaaatc	gcaattgggt	gcagaaccca	420
tctcttatct	ccaatctctc	gaaatccagt	caacgcaaat	ctcccttctc	ggtttctctg	480
aagacgcagc	agcatccacg	agcttatccg	atttcgtcgt	cgtggggatt	gaagaagagt	540
gggatgacgt	taattggctc	tgagcttcgt	ctctttaaag	tcattgtctc	tgtttccacg	600
gcggagaaaag	cgtcggagat	tgtacttcaa	ccacttagag	aaatctccgg	tcctattaag	660
cttctcgctc	ccaagtctct	atcaaatcgg	atcctgcttc	tcgtgctctc	gtctgaggtg	720
tatatatact	cgtttcgtcc	ttctctgtaa	tctgaactta	gattataaag	attgataact	780
taccattttg	ctgtggtttt	atagggaaac	actgtagtgg	acaacttgtt	gaatagcgat	840
gacatcaatt	acatgcttga	tcggttgaag	agattgggac	ttaattgtga	aactgacagt	900
gaaaaataatc	gtgctgtagt	tgaaaggatgt	ggcgggatat	tcccagcttc	catagattca	960
aagagtgtata	tcgaacttta	ctctcggtaat	gcagggaacag	caatgcgctc	acttaccgct	1020
gcggtcactg	ctgcaggtgg	aaacgcaagg	tagattgaaag	gagttgatgc	ttcttgggtat	1080
ttgatgttta	aggaatggag	cttttcttga	tgctttatga	tcatttattt	ccagtctatgt	1140
gcttgatggg	gtgcctcgta	tgagagaaaag	acctataggg	gatttggctg	ttggctcttaa	1200
gcagcttggt	gctgatgttg	aatgtactct	tggaaactaac	tgccctcctg	ttcgtgtcaa	1260
cgctaattgt	ggccttcccg	gtggaagggt	tagatctttg	aaatggcgatg	tgaatatgta	1320
atctcgttcc	ttactcttatg	aaacttgcga	gaaatgtgtg	ttcatcatag	ccttagcttg	1380
acaagatttc	agtttttaat	ctactctcaa	cggatggatc	ctaaaaataga	atcggaattg	1440
gtgatgtggt	ttcgttctcg	attaccgttt	tcgttgatg	atttcttgat	taacaattag	1500
gagacattgt	atgcatttgc	aggtgaagct	ttctggatca	attagttagt	agtacttgac	1560
tgctctgtct	atgtctgtct	ccttagctct	tgtagacgtc	gagattgaga	ttgtcgataa	1620
attaattttc	gttccatatt	tfgaaatgac	attgaagtgt	atggaacgtt	tcggggttag	1680
tgctcagcat	agtgatagct	gggatcgctt	ctttgtcaag	ggcgggcaca	aatcacaagt	1740
ggagtttatc	ttttcttctc	tttctgaaat	cacatccctt	agcttgacaa	tataatgact	1800

```

aaaagggtgaa  tgattcaggt  ctccggggtaa  tgcgtatgta  gaagggtgatg  cttctagtgc  1860
atgtttatttc  ttggctgggtg  ctgccatttac  cggtgaaact  gtcacagtcg  aagggtgtgg  1920
aactaccagc   ttgcaggttaa  tatttgtaca  ctgaatcatc  gacgaggctg  ttaagtttat  1980
agtgaatttc   gtctaggtcaa  aagtttcatc  ttttgacaag  ttgtatataa  catattcgca  2040
agatttcaag   ctcaattttt  gtgatgaatc  tctagggaga  tgtaaaattc  gccgaggctc  2100
ttgagaaaaa   gggatgtaaa  gtgtcctgga  cagagaacag  tgtgactgtg  acaggaccac  2160
ctagagatgc   ttttggaaatg  agacacttgc  gggctattga  tgtcaacatg  aacaaaatgc  2220
ctgatgtagc   catgaccott  gccgtcgttg  cttcttttgc  tgacggtcca  accaccatta  2280
gagatggtaa   gtaaaaagct  ctctcttata  attaaggttt  ctcaaatatt  atgatcactt  2340
aattctgttt   ggtaaatata  gtggctagct  ggagagataa  ggagacagaa  aggatgattg  2400
ccatttgcaac  agaagcttaga  aaagtaagag  attcttatct  ctctctttct  gtctcttgac  2460
agtgtcatt    ctaagtaatt  agctcataaa  tttgtgtgtt  tgtgttcacg  tgggagctac  2520
agtggaaaga   ggttcagatt  attgtgtgat  aactccgccc  aaaaagggtga  aaacggcaga  2580
gattgataca   tatgatgatc  atagaatggc  aatggcatcc  tctcttgcag  cttgtgctga  2640
tgttccaatc   accatcaacg  actctgtgtg  caccaggaaa  accctccccg  actacttcca  2700
aggtattgaa   agaatcacia  agcactaaac  aataaactct  gttttttctt  ctgatccaag  2760
ctt

```

```

<210> 2
<211> 520
<212> PRT
<213> Arabidopsis thaliana

```

```

<400> 2
Met Ala Gln Val Ser Arg Ile Cys Asn Gly Val Gln Asn Pro Ser Leu
1      5      10      15
Ile Ser Asn Leu Ser Lys Ser Ser Gln Arg Lys Ser Pro Leu Ser Val
20     25     30
Ser Leu Lys Thr Gln Gln His Pro Arg Ala Tyr Pro Ile Ser Ser Ser
35     40     45
Trp Gly Leu Lys Lys Ser Gly Met Thr Leu Ile Gly Ser Glu Leu Arg
50     55     60
Pro Leu Lys Val Met Ser Ser Val Ser Thr Ala Glu Lys Ala Ser Glu
65     70     75     80
Ile Val Leu Gln Pro Ile Arg Glu Ile Ser Gly Leu Ile Lys Leu Pro
85     90     95
Gly Ser Lys Ser Leu Ser Asn Arg Ile Leu Leu Ala Ala Leu Ser
100    105    110
Glu Gly Thr Thr Val Val Asp Asn Leu Leu Asn Ser Asp Asp Ile Asn
115    120    125
Tyr Met Leu Asp Ala Leu Lys Arg Leu Gly Leu Asn Val Glu Thr Asp
130    135    140
Ser Glu Asn Asn Arg Ala Val Val Glu Gly Cys Gly Gly Ile Phe Pro
145    150    155    160
Ala Ser Ile Asp Ser Lys Ser Asp Ile Glu Leu Tyr Leu Gly Asn Ala
165    170    175
Gly Thr Ala Met Arg Pro Leu Thr Ala Ala Val Thr Ala Ala Gly Gly
180    185    190
Asn Ala Ser Tyr Val Leu Asp Gly Val Pro Arg Met Arg Glu Arg Pro
195    200    205
Ile Gly Asp Leu Val Val Gly Leu Lys Gln Leu Gly Ala Asp Val Glu
210    215    220
Cys Thr Leu Gly Thr Asn Cys Pro Pro Val Arg Val Asn Ala Asn Gly
225    230    235    240
Gly Leu Pro Gly Gly Lys Val Lys Leu Ser Gly Ser Ile Ser Ser Gln
245    250    255
Tyr Leu Thr Ala Leu Leu Met Ser Ala Pro Leu Ala Leu Gly Asp Val
260    265    270

```

Glu Ile Glu Ile Val Asp Lys Leu Ile Ser Val Pro Tyr Val Glu Met
 275 280 285
 Thr Leu Lys Leu Met Glu Arg Phe Gly Val Ser Val Glu His Ser Asp
 290 295 300
 Ser Trp Asp Arg Phe Phe Val Lys Gly Gly Gln Lys Tyr Lys Ser Pro
 305 310 315 320
 Gly Asn Ala Tyr Val Glu Gly Asp Ala Ser Ser Ala Cys Tyr Phe Leu
 325 330 335
 Ala Gly Ala Ala Ile Thr Gly Glu Thr Val Thr Val Glu Gly Cys Gly
 340 345 350
 Thr Thr Ser Leu Gln Gly Asp Val Lys Phe Ala Glu Val Leu Glu Lys
 355 360 365
 Met Gly Cys Lys Val Ser Trp Thr Glu Asn Ser Val Thr Val Thr Gly
 370 375 380
 Pro Pro Arg Asp Ala Phe Gly Met Arg His Leu Arg Ala Ile Asp Val
 385 390 395 400
 Asn Met Asn Lys Met Pro Asp Val Ala Met Thr Leu Ala Val Val Ala
 405 410 415
 Leu Phe Ala Asp Gly Pro Thr Thr Ile Arg Asp Val Ala Ser Trp Arg
 420 425 430
 Val Lys Glu Thr Glu Arg Met Ile Ala Ile Cys Thr Glu Leu Arg Lys
 435 440 445
 Leu Gly Ala Thr Val Glu Glu Gly Ser Asp Tyr Cys Val Ile Thr Pro
 450 455 460
 Pro Lys Lys Val Lys Thr Ala Glu Ile Asp Thr Tyr Asp Asp His Arg
 465 470 475 480
 Met Ala Met Ala Phe Ser Leu Ala Ala Cys Ala Asp Val Pro Ile Thr
 485 490 495
 Ile Asn Asp Ser Gly Cys Thr Arg Lys Thr Phe Pro Asp Tyr Phe Gln
 500 505 510
 Val Leu Glu Arg Ile Thr Lys His
 515 520

<210> 3
 <211> 33
 <212> DNA
 <213> Arabidopsis thaliana

<220>
 <221> CDS
 <222> (1) ... (33)

<400> 3
 ctc ggt aat gca gca aca gca atg cgt cca ctt
 Leu Gly Asn Ala Ala Thr Ala Met Arg Pro Leu
 1 5 10

33

<210> 4
 <211> 11
 <212> PRT
 <213> Arabidopsis thaliana

<400> 4
 Leu Gly Asn Ala Ala Thr Ala Met Arg Pro Leu
 1 5 10

<210> 5

<211> 33
<212> DNA
<213> Arabidopsis thaliana

<220>
<221> CDS
<222> (1)...(33)

<400> 5
ctc ggt aat gca gga ata gca atg cgt cca ctt
Leu Gly Asn Ala Gly Ile Ala Met Arg Pro Leu
1 5 10

33

<210> 6
<211> 11
<212> PRT
<213> Arabidopsis thaliana

<400> 6
Leu Gly Asn Ala Gly Ile Ala Met Arg Pro Leu
1 5 10

<210> 7
<211> 33
<212> DNA
<213> Arabidopsis thaliana

<220>
<221> CDS
<222> (1)...(33)

<400> 7
ctc ggt aat gca gca ata gca atg cgt cca ctt
Leu Gly Asn Ala Ala Ile Ala Met Arg Pro Leu
1 5 10

33

<210> 8
<211> 11
<212> PRT
<213> Arabidopsis thaliana

<400> 8
Leu Gly Asn Ala Ala Ile Ala Met Arg Pro Leu
1 5 10

<210> 9
<211> 33
<212> DNA
<213> Arabidopsis thaliana

<220>
<221> CDS
<222> (1)...(33)

<400> 9

ctc ggt aat gca gga ata gca atg cgt tca ctt
 Leu Gly Asn Ala Gly Ile Ala Met Arg Ser Leu
 1 5 10

33

<210> 10
 <211> 11
 <212> PRT
 <213> Arabidopsis thaliana

<400> 10
 Leu Gly Asn Ala Gly Ile Ala Met Arg Ser Leu
 1 5 10

<210> 11
 <211> 33
 <212> DNA
 <213> Arabidopsis thaliana

<220>
 <221> CDS
 <222> (1)...(33)

<400> 11
 ctc ggt aat gca gca aca gca atg cgt tca ctt
 Leu Gly Asn Ala Ala Thr Ala Met Arg Ser Leu
 1 5 10

33

<210> 12
 <211> 11
 <212> PRT
 <213> Arabidopsis thaliana

<400> 12
 Leu Gly Asn Ala Ala Thr Ala Met Arg Ser Leu
 1 5 10

<210> 13
 <211> 33
 <212> DNA
 <213> Arabidopsis thaliana

<220>
 <221> CDS
 <222> (1)...(33)

<400> 13
 ctc ggt aat gca gca ata gca atg cgt tca ctt
 Leu Gly Asn Ala Ala Ile Ala Met Arg Ser Leu
 1 5 10

33

<210> 14
 <211> 11
 <212> PRT
 <213> Arabidopsis thaliana

<400> 14
Leu Gly Asn Ala Ala Ile Ala Met Arg Ser Leu
1 5 10

<210> 15
<211> 33
<212> DNA
<213> Arabidopsis thaliana

<220>
<221> CDS
<222> (1)...(33)

<400> 15
ctc ggt aat gca gga gta gca atg cgt tca ctt
Leu Gly Asn Ala Gly Val Ala Met Arg Ser Leu
1 5 10

33

<210> 16
<211> 11
<212> PRT
<213> Arabidopsis thaliana

<400> 16
Leu Gly Asn Ala Gly Val Ala Met Arg Ser Leu
1 5 10

<210> 17
<211> 33
<212> DNA
<213> Arabidopsis thaliana

<220>
<221> CDS
<222> (1)...(33)

<400> 17
ctc ggt aat gca gga tta gca atg cgt tca ctt
Leu Gly Asn Ala Gly Leu Ala Met Arg Ser Leu
1 5 10

33

<210> 18
<211> 11
<212> PRT
<213> Arabidopsis thaliana

<400> 18
Leu Gly Asn Ala Gly Leu Ala Met Arg Ser Leu
1 5 10

<210> 19
<211> 33
<212> DNA
<213> Arabidopsis thaliana

<220>

<221> CDS
<222> (1)...(33)

<400> 19
ctc ggt aat gca gca gta gca atg cgt cca ctt 33
Leu Gly Asn Ala Ala Val Ala Met Arg Pro Leu
1 5 10

<210> 20
<211> 11
<212> PRT
<213> Arabidopsis thaliana

<400> 20
Leu Gly Asn Ala Ala Val Ala Met Arg Pro Leu
1 5 10

<210> 21
<211> 33
<212> DNA
<213> Arabidopsis thaliana

<220>
<221> CDS
<222> (1)...(33)

<400> 21
ctc ggt aat gca gca tta gca atg cgt cca ctt 33
Leu Gly Asn Ala Ala Leu Ala Met Arg Pro Leu
1 5 10

<210> 22
<211> 11
<212> PRT
<213> Arabidopsis thaliana

<400> 22
Leu Gly Asn Ala Ala Leu Ala Met Arg Pro Leu
1 5 10

<210> 23
<211> 3831
<212> DNA
<213> Brassisca napus

<220>
<221> modified_base
<222> 1...3831
<223> n=a, c, g, or t

<400> 23
agatcttaaa ggctcttttc cagtctcacc taccaaaaact ataagaaaat ccacttgctg 60
tctgaaatag ccgacgtgga taaagtactt aagacgtggc acattattat tggctactag 120
aaaaaaaact catacaccat cgtaggagtt ggggttggtg aagaatttga tgggtgcctc 180
tccccccccc actcaccaaa ctcatgttct ttgtaaaagc gtcactacaa caacaaagga 240
gacgacagtt ctatagaaaa gctttcaaat tcaatcaatg gcgcaatcta gcagaatctg 300

ccatggcggtg	cagaaacccat	gtgttatcat	ctccaatctc	tccaaatcca	acccaaacaa	360
atcaccttct	tccgtctcct	tgaagacgca	tcagcctcga	gcttctctgt	ggggattgaa	420
gaagagtggg	acgatgtctaa	acggttctgt	aattcgcccg	gttaagggtaa	cagcttctgt	480
ttccagctcc	gagaaagctt	cagagattgt	gcttcaacca	atcagagaaa	ctctgggtct	540
cattaaagcta	cccgatccca	aatctctctc	caatcggtac	ctccttctgt	cgcctctatc	600
tgaggtagcat	atacttgctt	agtgtaggcg	ctttgctgtg	agatttttgg	aactatagac	660
aatttagtaa	gaatttatat	ataatttttt	taaaaaaaat	cagaagcctc	tatatattta	720
aatttttcca	aaatttttgg	aggttatagg	ettatgttac	accattctag	tctgcatctt	780
tcggttttag	actgaagatt	tttatttttt	aaaaaattat	tataggggaa	tactgtagtgt	840
gacaacttgt	tgaacagtga	tgacatcaac	tacatgcttg	atgcgttgaa	gaagctgggg	900
cttaacgtgg	aacgtgacag	tgtaaaacaac	cgtgcgggtg	ttgaagagtg	cgggtggaata	960
ttccagcttg	cccttagatt	caagagtgtg	attgagtgtg	accttgggaa	tcaggaacaa	1020
gccatgcgtc	cactcacccg	tgcagttaca	gctgcaggtg	gcaacgcgag	gtaagggttaa	1080
cgaatttttt	gtttattgtca	agaaattgat	cttgtgtttg	atgcttttag	ttgtgtttgt	1140
ttctagttaa	tgtacttgtat	gggtgctcta	gaatgaggga	aagacacctata	ggagattttgg	1200
ttgtgtgtct	taagcagctt	ggtgctgatg	ttgagtgtac	tcttggcacta	aactgtccctc	1260
ctgttcgtgt	caatgctaat	gggtgccttc	ccggtggaaa	gggtgacttc	acatttactc	1320
tatgaattgt	ttgcagcagt	ctttgttcat	cacagccttt	gcttcacatt	atttcatctt	1380
ttagttttgt	gtttattttac	ttgatggatc	tttaaaaagg	aattgggtct	gggtgtgaaag	1440
tgattagcaa	tctttctcga	ttccttgtag	ggccgtggcg	attacttaag	gaaacattct	1500
ctcatttaacc	ccccaaattt	ttgaaaaaaa	tttagtatat	ggccccaaaa	tagtgttttta	1560
aaaaattaga	aaaaactttta	ataaatcgct	tacagtccon	naaatcttag	agccggccct	1620
gcttgtagtt	tttctcgatt	gatatattag	actatgtttt	gaatttttca	gtgaagcttt	1680
ctggatcgat	cagtagtcag	tacttgactg	ccctccctcat	ggcagctccct	ttagctcttg	1740
gagacgtgga	gattgagatc	attgataaac	tgatatctgt	tccatattgt	gaaatgacat	1800
tgagattgat	ggagcgtttt	gggtgttagt	ccgagcatag	tgcatactgg	tactgtttct	1860
ttgtcagggg	cggtcagaaa	tacaagtaat	gagttctttt	aagtgtgagag	ttagattgaa	1920
gaatgaatga	ctgatttaaac	aaatggccaa	actgattcag	gtcgcctggg	aatgcttatg	1980
tagaagggtga	tgcctctagt	gctagctatt	tcttggctgg	tgctgccaat	actggtgaaa	2040
ctgtttactgt	cgaagggtgt	ggaaacaacta	gcctccaggt	agttttatcca	ctctgaatca	2100
tcaaatattta	ttctccctcc	gttttatgtt	aagtgctcat	agctttttcaa	ttttgtttca	2160
ttaaaagtgt	tctttttacat	tttcaatgca	tatatataat	aaatttttcaa	gtttttacta	2220
attcattaat	tagcaaaatc	aaacaaaaat	tatatataat	aatgtaaaat	tcgtaattgt	2280
tgtgcaaaaa	ccttaaacct	tatgaaacgg	aaaccttatg	aaacagaggg	agtactaatt	2340
ttataataaaa	attttgattag	ttcaaaagttg	tgtataacat	gttttgttaag	aatctaaagt	2400
catttctcttt	ttattttttt	tgatgaatcc	aaagggagat	gtgaaattcg	cagaggttct	2460
tgagaaaaatg	ggatgtataag	tgtcatggac	agagaacagt	gtgactgtga	ctggaccact	2520
aagagatgct	tttggaaatga	ggcacttgcg	tgctgttgat	gtcaacatga	acaaaatgcc	2580
tgatgtagcc	atgactctag	ccgttgttgc	tctctttgoc	gatggtccaa	ccaccatcag	2640
agatggtaaa	gcaaaacccct	ctctttgaat	cagcgtgttt	taaaaggattc	atgggttgcct	2700
aaactcattt	tggtcaatgt	agtggttagc	tggaaggtta	aggagacaga	gaggatgaat	2760
gccatttgca	cagagcttag	aaaggtaagt	ttccttttct	ctcatgcctc	agctattcgaa	2820
gttaatcggt	gcataacctt	ttgctggttt	tttttttggc	ttcagcttgg	ctcatcacagt	2880
gaagaaggct	cagatttatg	tgtgataact	ccaccagcaa	agggtgaaacc	ggcggagatt	2940
tgatcagtat	atgatcatag	taatggcgatg	cggttctcgc	ttgcagctgt	tgctgtatgt	3000
ccagtcaacca	tcaaggatcc	tggctgcacc	aggaagactt	ttcctgacta	cttccaagtt	3060
cttgaaagtta	tcacaaagca	ttaaaagacc	cttctctctg	atccaaatgt	gagaattctgt	3120
tgtttctctt	tgtttgcac	tgtaacattt	attagaagaa	caaagtgtgt	gtgttaagag	3180
tgtgttttgt	tgtaatgaac	tgagttagat	gcaatcgttg	aatcagtttt	gggccttaat	3240
aaaggggttta	ggaagctgca	cgagatgat	gtttttttgt	cgatcatctt	tgaaaattgtg	3300
tttgttttag	taattttttct	agggtttagt	tgattacact	aagaaacctt	ttttgatttt	3360
ctattacacc	tatagacact	ctttacatgt	gacacacttt	gttgtttgca	agcaaacagat	3420
tgtggacaa	tctgctttta	tctggaaagaa	cacagttgtg	tgatgggtgt	ttgtggacga	3480
ttccattgat	gggttaggggt	attttgtgac	ggatgatgtg	tagatagagt	atagatgaatg	3540
tgtgaatagt	tgtgtttaat	gtgtttatag	tagataagtg	gacaaacctc	ctgttttgat	3600
tcataaaaa	tatacaacaa	tacgtggaca	tggactcatg	ttactaaaa	tataccgttaa	3660
aacgtggcga	cgcagcttgt	atctccaata	caaacacgtg	gcttcttcag	ctcaatttgat	3720
aaatttatctg	cagtttaact	tcaatcaaga	tgaaaagag	atgatatgtg	gaatatgagc	3780

<210> 24
 <211> 1944
 <212> DNA
 <213> *Petunia hybrida*

<400> 24

gaattccctc	aatcctttact	ttcaagaatg	gcacaaaatta	acaacatggc	tcaaggsgata	60
gaaccoccta	atcccaatct	caattttccat	aaaccccaag	ttcctaatac	ttcaagtttt	120
ctgtgttttt	gatctaaaaa	actgaaaaat	tcagcaaatc	ctatgtgtgt	tttgaaaaaa	180
gattcaattt	ttatgcaaaa	gttttgttcc	tttaggattc	cagcatcagc	ggctcacagca	240
cagaagcctt	ctgagatagt	gttgcaaccc	attaaagaga	tttcaggcac	tgtaaattgt	300
ctgtgctcta	aatcattatc	taatagaatt	ctccttcttg	ctgccttata	tgaaggaaaca	360
actgtggttg	acaattttact	agtagtgat	gatattcatt	acatgcttgg	tgcttggaaa	420
acacttggac	tgcatgtaga	agaagatagt	gcaaaccaac	gagctgttgt	tgaaggttgt	480
ggtgggcttt	tcctctgttg	taaagagtcc	aaggaagaaa	ttcaactgtt	ccttggaaat	540
gcaggaacag	caatgcggcc	actaacagca	gcagttactg	tagctgggtg	aaattcaagg	600
tatgtacttg	atggagttcc	tcgaatgaga	gagagaccaa	ttagtatttt	ggttgatggg	660
cttaaacagc	ttggtgcaga	ggttgattgt	ttccttggtg	cgaaatgtcc	tcctgttcga	720
atgtgcagca	agggaggtct	tcctggaggg	aaggtcaagc	ttctctggatc	cattagcagc	780
caatacttga	ctgctctgtc	tatggctgct	ccactggctt	taggagatgt	ggagattgaa	840
atcatgtaca	aactaaatag	tgtaccttat	gtcgagatga	cattgaagtt	gatggagcga	900
tttggttatt	ctgtggagca	cagtagtagc	tgggacaggt	tccttctccg	aggaggtcag	960
aaatacaagt	ctcctggaaa	agcttttgtc	gaaggtgatg	cttcaagtcg	tagctacttc	1020
ttggctggtg	cagcagtcac	aggtggaaat	atcattgttg	aaggtgtgtg	gacaaacagt	1080
ttacaggggg	gtgtcaaat	tgctgaggta	cctgaaaaaa	tgggagctga	agttactgtg	1140
acagagaaca	gtgtcacagt	caaaaggact	ccaaggagtt	cttctggggg	gaagcatttg	1200
ctgtgccattg	atgtgaacat	gaataaaaatg	ctgatgtgtg	ccatgacact	tgctgttgtt	1260
gcactttatg	ctgatgtgtc	cacagctata	agagatgttg	ctagctggag	agtcaaggaa	1320
actgagcgca	tgatcgccat	atgcacagaa	cttaggaagt	taggagcaac	cgttgaagaa	1380
ggaccagact	actgcataat	cacccacacg	gagaaaactaa	atgtgaccca	tattgataca	1440
tacgatgatc	acaggatggc	catggctttt	ttcttctgtc	cttgtgcaga	tggtcccgct	1500
accatcaatg	acccctggctg	cacgcggaaa	accttcccta	actactttga	tgtaactcag	1560
cagtaactcca	agcattgaac	cgcttcccta	tattgcagaa	tgtaagtaag	aatatgtgaa	1620
gagttttagt	ctgttacaag	acaggctacg	actgcctggg	atcagaacca	caatgggttc	1680
catttcagtt	cagaaggcca	ttccaaggct	tcgaactcct	tactattttg	cgagtgtatga	1740
aatgtatttg	ttagagttga	gcttcttttt	gtctttaaagg	aatgtacact	aatagagtta	1800
agaattacta	gtatgggcca	gtgtaaggag	tactattact	cttgtcttat	ttattgtatt	1860
gagttttgtc	aaggatctgg	ctttgtcaag	aattactggt	taattttatt	gacaactctca	1920
tgtgtctaaa	tgaatttgtt	tgat				1944

<210> 25
 <211> 1335
 <212> DNA
 <213> *Zea mays*

<400> 25

gcgggtgccc	aggagatcgt	gctgcagccc	atcaaggaga	tctccggcac	cgtcaagctg	60
ccggggtcca	agtcgctttc	caaccggatc	ctcctaactc	cgccctgtgc	cgaggggaca	120
acagtgggtg	ataaacctgt	gaacagtggg	gatgtccact	acatgctcgg	ggccttgagg	180
actcttggtc	tctctgtctg	acgcgacaaa	gctgcacaaa	gagctgtagt	tgttgcctgt	240
ggtggaaagt	tcccagtgtg	ggaatgctaaa	gagggaagtgc	agctcttctt	ggggaaatgt	300
ggaactgcga	tggtggccat	gacagcagct	gttactgtgt	ctgggtggaaa	tgcaactctac	360
gtgctgtgat	gagtaaccaag	aatgaggagg	agaccatttg	gcgactctgt	tgctcgattg	420
aagcagcttg	gtgcagatgt	tgattgtttc	cttggcactg	actgcccacc	tgtctgtgtc	480
aatgtgaatc	gagggtctacc	gtgtggcagg	gtcaagctgt	gagctcccat	cagactctcag	540
tacttgatgt	cctgtctgat	ggctgctcct	ttggctcttg	gggatgtgga	gattgaaatc	600

attgataaat	taattctccat	tccgtacgtc	gaaatgacat	tgagattgat	ggagcgtttt	660
ggtgtgaaag	cagagcattc	tgatagctgg	gacagattct	acattaaggg	aggtcaaaaa	720
tacaagtc	ctaaaaatgc	ctatgttgaa	ggtgatgcct	caagcgcaag	ctatttcttg	780
gctggtgctg	caattactgg	agggactgtg	actgtggaag	gttggtggcac	caccagtttg	840
caggggtgatg	tgaagtttgc	tgaggtactg	gagatgatgg	gagcggaaggt	tacatggacc	900
gagactagcg	taactgtttac	tggcccaccg	cgggagccat	ttggggagaa	acacctcaag	960
gcgattgatg	tcaacatgaa	caagatgcct	gatgtcgcca	tgactcttgc	ttgggttgcc	1020
ctctttgccc	atggcccgac	agccatcaga	gacgtggctt	cctggagagt	aaaggagacc	1080
gagaggatgg	ttgcgatccg	gacggagcta	accaagctgg	gagcatctgt	tgaggaaaggg	1140
cggactactc	gcattcatcac	gccgccggag	aagctgaacg	tgacggcgat	cgacacgtac	1200
gacgaccaca	ggatggccat	ggcctctcc	cttgcgcgct	gtgccgaggt	ccccgtcacc	1260
atccgggacc	ctgggtgcac	ccggaagacc	ttccccgact	acttcgatgt	gctgagcact	1320
ttcgtcaaga	attaa					1335

<210> 26

<211> 516

<212> PRT

<213> *Brassica napus*

<400> 26

Met	Ala	Gln	Ser	Ser	Arg	Ile	Cys	His	Gly	Val	Gln	Asn	Pro	Cys	Val
1				5					10					15	
Ile	Ile	Ser	Asn	Leu	Ser	Lys	Ser	Asn	Gln	Asn	Lys	Ser	Pro	Phe	Ser
			20					25					30		
Val	Ser	Leu	Lys	Thr	His	Gln	Pro	Arg	Ala	Ser	Ser	Trp	Gly	Leu	Lys
			35				40					45			
Lys	Ser	Gly	Thr	Met	Leu	Asn	Gly	Ser	Val	Ile	Arg	Pro	Val	Lys	Val
			50			55				60					
Thr	Ala	Ser	Val	Ser	Thr	Ser	Glu	Lys	Ala	Ser	Glu	Ile	Val	Leu	Gln
65					70				75					80	
Pro	Ile	Arg	Glu	Ile	Ser	Gly	Leu	Ile	Lys	Leu	Pro	Gly	Ser	Lys	Ser
			85					90						95	
Leu	Ser	Asn	Arg	Ile	Leu	Leu	Leu	Ala	Ala	Leu	Ser	Glu	Gly	Thr	Thr
			100					105					110		
Val	Val	Asp	Asn	Leu	Leu	Asn	Ser	Asp	Asp	Ile	Asn	Tyr	Met	Leu	Asp
			115					120				125			
Ala	Leu	Lys	Lys	Leu	Gly	Leu	Asn	Val	Glu	Arg	Asp	Ser	Val	Asn	Asn
			130				135					140			
Arg	Ala	Val	Val	Glu	Gly	Cys	Gly	Gly	Ile	Phe	Pro	Ala	Ser	Leu	Asp
					150					155				160	
Ser	Lys	Ser	Asp	Ile	Glu	Leu	Tyr	Leu	Gly	Asn	Ala	Gly	Thr	Ala	Met
			165					170						175	
Arg	Pro	Leu	Thr	Ala	Ala	Val	Thr	Ala	Gly	Gly	Asn	Ala	Ser	Tyr	
			180					185					190		
Val	Leu	Asp	Gly	Val	Pro	Arg	Met	Arg	Glu	Arg	Pro	Ile	Gly	Asp	Leu
		195					200					205			
Val	Val	Gly	Leu	Lys	Gln	Leu	Gly	Ala	Asp	Val	Glu	Cys	Thr	Leu	Gly
		210					215				220				
Thr	Asn	Cys	Pro	Pro	Val	Arg	Val	Asn	Ala	Asn	Gly	Gly	Leu	Pro	Gly
225					230					235				240	
Gly	Lys	Val	Lys	Leu	Ser	Gly	Ser	Ile	Ser	Ser	Gln	Tyr	Leu	Thr	Ala
				245						250				255	
Leu	Leu	Met	Ala	Ala	Pro	Leu	Ala	Leu	Gly	Asp	Val	Glu	Ile	Glu	Ile
			260					265					270		
Ile	Asp	Lys	Leu	Ile	Ser	Val	Pro	Tyr	Val	Glu	Met	Thr	Leu	Lys	Leu
			275					280					285		
Met	Glu	Arg	Phe	Gly	Val	Ser	Ala	Glu	His	Ser	Asp	Ser	Trp	Asp	Arg
	290					295					300				

Phe Phe Val Lys Gly Gly Gln Lys Tyr Lys Ser Pro Gly Asn Ala Tyr
 305 310 315 320
 Val Glu Gly Asp Ala Ser Ser Ala Ser Tyr Phe Leu Ala Gly Ala Ala
 325 330 335
 Ile Thr Gly Glu Thr Val Thr Val Glu Gly Cys Gly Thr Thr Ser Leu
 340 345 350
 Gln Gly Asp Val Lys Phe Ala Glu Val Leu Glu Lys Met Gly Cys Lys
 355 360 365
 Val Ser Trp Thr Glu Asn Ser Val Thr Val Thr Gly Pro Ser Arg Asp
 370 375 380
 Ala Phe Gly Met Arg His Leu Arg Ala Val Asp Val Asn Met Asn Lys
 385 390 395
 Met Pro Asp Val Ala Met Thr Leu Ala Val Val Ala Leu Phe Ala Asp
 405 410 415
 Gly Pro Thr Thr Ile Arg Asp Val Ala Ser Trp Arg Val Lys Glu Thr
 420 425 430
 Glu Arg Met Ile Ala Ile Cys Thr Glu Leu Arg Lys Leu Gly Ala Thr
 435 440 445
 Val Glu Glu Gly Ser Asp Tyr Cys Val Ile Thr Pro Pro Ala Lys Val
 450 455 460
 Lys Pro Ala Glu Ile Asp Thr Tyr Asp Asp His Arg Met Ala Met Ala
 465 470 475
 Phe Ser Leu Ala Ala Cys Ala Asp Val Pro Val Thr Ile Lys Asp Pro
 485 490 495
 Gly Cys Thr Arg Lys Thr Phe Pro Asp Tyr Phe Gln Val Leu Glu Ser
 500 505 510
 Ile Thr Lys His
 515

<210> 27

<211> 516

<212> PRT

<213> Petunia hybrida

<400> 27

Met Ala Gln Ile Asn Asn Met Ala Gln Gly Ile Gln Thr Leu Asn Pro
 1 5 10 15
 Asn Ser Asn Phe His Lys Pro Gln Val Pro Lys Ser Ser Ser Phe Leu
 20 25 30
 Val Phe Gly Ser Lys Lys Leu Lys Asn Ser Ala Asn Ser Met Leu Val
 35 40 45
 Leu Lys Lys Asp Ser Ile Phe Met Gln Lys Phe Cys Ser Phe Arg Ile
 50 55 60
 Ser Ala Ser Val Ala Thr Ala Gln Lys Pro Ser Glu Ile Val Leu Gln
 65 70 75 80
 Pro Ile Lys Glu Ile Ser Gly Thr Val Lys Leu Pro Gly Ser Lys Ser
 85 90 95
 Leu Ser Asn Arg Ile Leu Leu Leu Ala Ala Leu Ser Glu Gly Thr Thr
 100 105 110
 Val Val Asp Asn Leu Leu Ser Ser Asp Asp Ile His Tyr Met Leu Gly
 115 120 125
 Ala Leu Lys Thr Leu Gly Leu His Val Glu Glu Asp Ser Ala Asn Gln
 130 135 140
 Arg Ala Val Val Glu Gly Cys Gly Gly Leu Phe Pro Val Gly Lys Glu
 145 150 155 160
 Ser Lys Glu Glu Ile Gln Leu Phe Leu Gly Asn Ala Gly Thr Ala Met
 165 170 175

Arg Pro Leu Thr Ala Ala Val Thr Val Ala Gly Gly Asn Ser Arg Tyr
 180 185 190
 Val Leu Asp Gly Val Pro Arg Met Arg Glu Arg Pro Ile Ser Asp Leu
 195 200 205
 Val Asp Gly Leu Lys Gln Leu Gly Ala Glu Val Asp Cys Phe Leu Gly
 210 215 220
 Thr Lys Cys Pro Pro Val Arg Ile Val Ser Lys Gly Gly Leu Pro Gly
 225 230 235 240
 Gly Lys Val Lys Leu Ser Gly Ser Ile Ser Ser Gln Tyr Leu Thr Ala
 245 250 255
 Leu Leu Met Ala Ala Pro Leu Ala Leu Gly Asp Val Glu Ile Glu Ile
 260 265 270
 Ile Asp Lys Leu Ile Ser Val Pro Tyr Val Glu Met Thr Leu Lys Leu
 275 280 285
 Met Glu Arg Phe Gly Ile Ser Val Glu His Ser Ser Ser Trp Asp Arg
 290 295 300
 Phe Phe Val Arg Gly Gly Gln Lys Tyr Lys Ser Pro Gly Lys Ala Phe
 305 310 315 320
 Val Glu Gly Asp Ala Ser Ser Ala Ser Tyr Phe Leu Ala Gly Ala Ala
 325 330 335
 Val Thr Gly Gly Thr Ile Thr Val Glu Gly Cys Gly Thr Asn Ser Leu
 340 345 350
 Gln Gly Asp Val Lys Phe Ala Glu Val Leu Glu Lys Met Gly Ala Glu
 355 360 365
 Val Thr Trp Thr Glu Asn Ser Val Thr Val Lys Gly Pro Pro Arg Ser
 370 375 380
 Ser Ser Gly Arg Lys His Leu Arg Ala Ile Asp Val Asn Met Asn Lys
 385 390 395 400
 Met Pro Asp Val Ala Met Thr Leu Ala Val Val Ala Leu Tyr Ala Asp
 405 410 415
 Gly Pro Thr Ala Ile Arg Asp Val Ala Ser Trp Arg Val Lys Glu Thr
 420 425 430
 Glu Arg Met Ile Ala Ile Cys Thr Glu Leu Arg Lys Leu Gly Ala Thr
 435 440 445
 Val Glu Glu Gly Pro Asp Tyr Cys Ile Ile Thr Pro Pro Glu Lys Leu
 450 455 460
 Asn Val Thr Asp Ile Asp Thr Tyr Asp Asp His Arg Met Ala Met Ala
 465 470 475 480
 Phe Ser Leu Ala Ala Cys Ala Asp Val Pro Val Thr Ile Asn Asp Pro
 485 490 495
 Gly Cys Thr Arg Lys Thr Phe Pro Asn Tyr Phe Asp Val Leu Gln Gln
 500 505 510
 Tyr Ser Lys His
 515

<210> 28
 <211> 444
 <212> PRT
 <213> Zea mays

<400> 28
 Ala Gly Ala Glu Glu Ile Val Leu Gln Pro Ile Lys Glu Ile Ser Gly
 1 5 10 15
 Thr Val Lys Leu Pro Gly Ser Lys Ser Leu Ser Asn Arg Ile Leu Leu
 20 25 30
 Leu Ala Ala Leu Ser Glu Gly Thr Thr Val Val Asp Asn Leu Leu Asn
 35 40 45

Ser Glu Asp Val His Tyr Met Leu Gly Ala Leu Arg Thr Leu Gly Leu
 50 55 60
 Ser Val Glu Ala Asp Lys Ala Ala Lys Arg Ala Val Val Val Gly Cys
 65 70 75 80
 Gly Gly Lys Phe Pro Val Glu Asp Ala Lys Glu Glu Val Gln Leu Phe
 85 90 95
 Leu Gly Asn Ala Gly Thr Ala Met Arg Pro Leu Thr Ala Ala Val Thr
 100 105 110
 Ala Ala Gly Gly Asn Ala Thr Tyr Val Leu Asp Gly Val Pro Arg Met
 115 120 125
 Arg Glu Arg Pro Ile Gly Asp Leu Val Val Gly Leu Lys Gln Leu Gly
 130 135 140
 Ala Asp Val Asp Cys Phe Leu Gly Thr Asp Cys Pro Pro Val Arg Val
 145 150 155 160
 Asn Gly Ile Gly Gly Leu Pro Gly Gly Lys Val Lys Leu Ser Gly Ser
 165 170 175
 Ile Ser Ser Gln Tyr Leu Ser Ala Leu Leu Met Ala Ala Pro Leu Ala
 180 185 190
 Leu Gly Asp Val Glu Ile Glu Ile Ile Asp Lys Leu Ile Ser Ile Pro
 195 200 205
 Tyr Val Glu Met Thr Leu Arg Leu Met Glu Arg Phe Gly Val Lys Ala
 210 215 220
 Glu His Ser Asp Ser Trp Asp Arg Phe Tyr Ile Lys Gly Gly Gln Lys
 225 230 235 240
 Tyr Lys Ser Pro Lys Asn Ala Tyr Val Glu Gly Asp Ala Ser Ser Ala
 245 250 255
 Ser Tyr Phe Leu Ala Gly Ala Ala Ile Thr Gly Gly Thr Val Thr Val
 260 265 270
 Glu Gly Cys Gly Thr Thr Ser Leu Gln Gly Asp Val Lys Phe Ala Glu
 275 280 285
 Val Leu Glu Met Met Gly Ala Lys Val Thr Trp Thr Glu Thr Ser Val
 290 295 300
 Thr Val Thr Gly Pro Pro Arg Glu Pro Phe Gly Arg Lys His Leu Lys
 305 310 315 320
 Ala Ile Asp Val Asn Met Asn Lys Met Pro Asp Val Ala Met Thr Leu
 325 330 335
 Ala Val Val Ala Leu Phe Ala Asp Gly Pro Thr Ala Ile Arg Asp Val
 340 345 350
 Ala Ser Trp Arg Val Lys Glu Thr Glu Arg Met Val Ala Ile Arg Thr
 355 360 365
 Glu Leu Thr Lys Leu Gly Ala Ser Val Glu Glu Gly Pro Asp Tyr Cys
 370 375 380
 Ile Ile Thr Pro Pro Glu Lys Leu Asn Val Thr Ala Ile Asp Thr Tyr
 385 390 395 400
 Asp Asp His Arg Met Ala Met Ala Phe Ser Leu Ala Ala Cys Ala Glu
 405 410 415
 Val Pro Val Thr Ile Arg Asp Pro Gly Cys Thr Arg Lys Thr Phe Pro
 420 425 430
 Asp Tyr Phe Asp Val Leu Ser Thr Phe Val Lys Asn
 435 440

<210> 29
 <211> 64
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Mutant primer

```

<400> 29
cgtttccacc tgcagcagtg accgcagcgg taagtggacg cattgctgtt gctgcattac 60
cgag 64

<210> 30
<211> 64
<212> DNA
<213> Artificial Sequence

<220>
<223> Mutant primer

<400> 30
cgtttccacc tgcagcagtg accgcagcgg taagtggacg cattgctatt gctgcattac 60
cgag 64

<210> 31
<211> 64
<212> DNA
<213> Artificial Sequence

<220>
<223> Mutant primer

<400> 31
cgtttccacc tgcagcagtg accgcagcgg taagtgaacg cattgctatt cctgcattac 60
cgag 64

<210> 32
<211> 64
<212> DNA
<213> Artificial Sequence

<220>
<223> Mutant primer

<400> 32
cgtttccacc tgcagcagtg accgcagcgg taagtgaacg cattgctgtt gctgcattac 60
cgag 64

<210> 33
<211> 64
<212> DNA
<213> Artificial Sequence

<220>
<223> Mutant primer

<400> 33
cgtttccacc tgcagcagtg accgcagcgg taagtgaacg cattgctatt gctgcattac 60
cgag 64

<210> 34
<211> 64
<212> DNA
<213> Artificial Sequence

<220>

```

```

<223> Mutant primer

<400> 34
cgtttccacc tgcagcagtg accgcagcgg taagtggacg cattgctgtt attgcattac 60
cgag 64

<210> 35
<211> 64
<212> DNA
<213> Artificial Sequence

<220>
<223> Mutant primer

<400> 35
cgtttccacc tgcagcagtg accgcagcgg taagtgaacg cattgctact cctgcattac 60
cgag 64

<210> 36
<211> 64
<212> DNA
<213> Artificial Sequence

<220>
<223> Mutant primer

<400> 36
cgtttccacc tgcagcagtg accgcagcgg taagtgaacg cattgctaact cctgcattac 60
cgag 64

<210> 37
<211> 64
<212> DNA
<213> Artificial Sequence

<220>
<223> Mutant primer

<400> 37
cgtttccacc tgcagcagtg accgcagcgg taagtggacg cattgctact gctgcattac 60
cgag 64

<210> 38
<211> 64
<212> DNA
<213> Artificial Sequence

<220>
<223> Mutant primer

<400> 38
cgtttccacc tgcagcagtg accgcagcgg taagtggacg cattgctaact gctgcattac 60
cgag 64

<210> 39
<211> 5
<212> PRT
<213> Petunia hybrida

```

<400> 39
 Leu Phe Leu Gly Asn
 1 5

<210> 40
 <211> 30
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Primer

<400> 40
 gctctagaga aagcgtcgga gattgtactt 30

<210> 41
 <211> 41
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Primer

<400> 41
 gcagatctga gctcttagtg ctttgtgatt ctttcaagta c 41

<210> 42
 <211> 28
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Primer

<400> 42
 gcgtctagaa aaacgagata aggtgcag 28

<210> 43
 <211> 38
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Primer

<400> 43
 gcggatcctc aggatttttt cgaaagctta tttaaatg 38

<210> 44
 <211> 20
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Primer

<400> 44
 gaaagcgtcg gagattgtac 20